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The liver is the vital organ for fat and carbohydrate metabolism as well as detoxification 
and excretion of metabolites. Any functional impairment will thus affect the whole 
organism and is absolutely undesirable. Nonalcoholic fatty liver disease (NAFLD) is a 
multifactorial worldwide disease which coincides with metabolic syndrome. The 
spectrum of NAFLD ranges from simple steatosis to nonalcoholic steatohepatitis 
(NASH), with consecutive fibrosis, cirrhosis, and might ultimately lead to hepatocellular 
carcinoma. The prevalence of NAFLD is estimated to be 20-30% of the general 
population in Europe, and it is paralleling with the increase in fructose consumption. 
Fructose, a monosaccharide, is naturally present in fruit, and it can be metabolized into 
glucose and lipid within the liver. Industrially, fructose is used in soft drinks as a 
sweetener, and it is integrated in pre-packed food as an additive. Fructose is considered 
a risk factor for NAFLD. Previous reports found an upregulation of liver lipocalin-2 
(LCN2) expression in inflammation and metabolic syndrome. LCN2 is a 25-kDa 
secretory glycoprotein, found abundantly in tissues that are exposed to microorganisms. 
It can bind a variety of lipophilic substances.  
Study motivations. Although ultrasonography, CT scan, and MRI are reliable tools for 
detecting a fatty liver, they are inadequate to classify the disease. Instead, a liver biopsy 
is needed to distinguish between simple steatosis and NASH. However, this is an 
invasive procedure which carries the risk of bleeding and injury to gallbladder, lungs and 
kidney. Thus, serum biomarkers would be most welcome. In addition, the pathogenesis 
of NAFLD is still poorly defined. The available animal models, such as Lcn2-/-, db/db, 
ob/ob, and ZF fa/fa do not mimic the physiological and/or histological features of NAFLD 
seen in humans. Since fructose is included in commercial/fast food as well as juice 
beverages and as it has been proposed to induce the most NAFLD manifestations 
noticed in humans; this study selected fructose as an inducer for metabolic syndrome 
and NAFLD.  
This study aimed to establish diet-induced fatty liver models in non-genetically-modified 
rats, to compare the expressional changes of inflammatory and metabolic parameters 
and LCN2 in these models, to explore whether serum LCN2 is a diagnostic indicator for 
NASH, and to investigate the potential mechanism(s) that induce(s) hepatic LCN2 
expression.  
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Male Sprague-Dawley rats were randomly assigned (n= 4 per group/ time point) as 
follows: chow pellets (control (Co)), liquid Lieber-DeCarli (LDC, high fat), and LDC + 
high (70% of the total calorie) fructose (L-HFr) diet. After feeding for 4 or 8 wks; the 
animals were deprived of any food 10 h before sacrifice.  
Blood from the vena cava and liver samples were harvested. Blood samples were 
examined for fasting glucose, lipid profile, serum transaminases activities, and leptin 
concentration. Histochemical studies for lipid deposition, inflammation, and fibrosis were 
performed on the liver sections. In addition, the hepatic transcript of Lcn2, the 
inflammatory mediators Il-8, Mcp-1 (Ccl2), alpha-2 macroglobulin (α2m), Tnf-α, Inos, 
Tlr4, and fructose transporter (Glut5) and leptin receptor (Lep-r) were evaluated by qRT-
PCR. Furthermore, ELISA and Western blots were performed to assess LCN2 levels in 
serum, while the localization of LCN2 in liver tissue was detected by double-
immunofluorescence staining. Western immunoblots for hepatic LCN2, CD14, IκB1α, 
pMAPK, casp 9, Cyt c, 4-hydroxynonenal (4-HNE adducts): by-products of lipid 
peroxidation, GRP78: an ER chaperone, and PGC-1α: a mitochondrial-biogenic protein, 
were carried out. In vitro experiments were done as well to study Lcn2 transcription. 
Primary hepatocytes (HCs) were isolated from control rats and cultured in M199 media 
supplemented with either 20 mM glucose or fructose for 0, 3, 6, 12, and 24 h.  
Hallmarks of the metabolic syndrome, including a significant elevation of fasting blood 
glucose and triglycerides as well as a decrease in HDL-cholesterol levels, were 
observed in the LHFr group. The activities of AST and ALT were augmented in L-HFr 
fed rats. Concurrently, feeding with L-HFr augmented fasting leptin levels by about 3-
fold vs. Co (P<0.001). Histologically, hepatic simple steatosis was featured in the LDC 
group. Parallel to the metabolic syndrome, the L-HFr group evidenced NASH criteria, 
such as inflammation (grade 2) and mild fibrosis (stage 2) in the portal triads, and 
hepatocellular ballooning in the centrilobular areas. Hepatic Glut5 and Lep-r expressions 
were substantially upregulated in the L-HFr group. While most tested biochemical 
parameters under the LDC regimen were slightly higher than in control rats, a significant 
increase in the plasma triglyceride level was seen in this group at wk 4.  
In the liver, specific transcripts of Mcp-1, α2-m, and Il-8 were increased in the L-HFr 
group at both time points (P<0.001), whereas the transcription of Tlr4, Inos, and Tnf-α 
was significantly enhanced at wk 4 and then dropped to the control level at wk 8. In 
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contrast, no significant change was observed in the LDC group. Interestingly, of the 
studied parameters, hepatic transcription of Lcn2 mRNA was the most pronounced (90- 
and 507-fold higher in the L-HFr rats vs. control at wk 4 and 8, respectively (P<0.001)). 
These data were further validated by Western blots. Of note, while hepatic LCN2 
expression reached its maximum at wk 8, the expression of inflammatory mediators in 
the liver decreased to control levels pointing to a possible hepatoprotective effect of 
LCN2. Likewise, a significant elevation of systemic LCN2 levels was observed in the L-
HFr regimen. In contrast to the mild changes seen in the LDC group, the hepatic 
expression of CD14, pMAPK, casp 9, Cyt c and 4-HNE proteins was increased in the L-
HFr group. Conversely, the expression of PGC-1α in the liver was reduced in the L-HFr 
group at wk 8. In the liver, the localization of LCN2 was restricted to MPO+ recruited 
granulocytes. LCN2 showed a high consecutive expression in fructose-treated primary 
HCs compared to glucose treatment. 
Conclusion 
Both LDC and L-HFr diets led NAFLD. While the LDC diet resulted in a simple steatosis, 
the L-HFr diet led to NASH. Fructose supplementation appears to worsen liver 
pathology. The features of the metabolic syndrome and NASH with progressive fibrosis 
obtained with fructose-enriched diet represent an animal model broadly similar to the 
conditions in human liver disease. These findings highlight the impact of dietary 
composition in the development of NAFLD. The fructose diet upregulates hepatic Lcn2 
gene expression in fructose-induced NASH. This correlates with the increased 
indicators of inflammation, oxidative stress and mitochondrial dysfunction. This novel 
study could introduce serum LCN2 as a useful new diagnostic to discriminate between 
simple steatosis and NASH. Evidently, an interaction exists between the metabolic 
impetus and inflammatory processes in the animals. The current model is valuable for 
investigation of the role(s) of LCN2 and other markers for inflammation and metabolism 
in greater depth and the development of new insights for preventing NASH. 
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1.1. Liver anatomy 
The human liver is located in the upper right quadrant of the abdomen, just under the 
diaphragm. It is the largest (1.5 - 1.8 kg in adult) organ of the body, accounting for 
approximately 2 - 3% of the average body weight.  
1.1.1. Liver macroscopy 
In humans, the liver consists of unequal right and left lobes divided by the falciform 
ligament, both of which are made up of thousands of lobules (Gregory and Wing 
2002). These are the functional units of the liver. Each lobule is about 1 mm in 
diameter. Liver lobules are hexagonal structures consisting of cords of hepatocytes 
that are separated by sinusoids. At each of the six corners of a lobule is a portal triad 
(branch of portal vein, branch of hepatic artery, and bile duct). The portal triad 
components with hepatic nerves plexus enter the liver via the so-called porta hepatis 
(a deep, transverse fissure on the right lobe). There are two distinct sources that 
supply blood to the liver (Figure 1.1), oxygenated blood flows through the hepatic 
artery (20%) and nutrient-rich blood flows from the hepatic portal vein (80%) (Tygstrup 
et al. 1962). There is also superficial and deep lymph drainage.  
 
Figure 1.1 Diagram of liver architecture (Seeley et al. 2008). 
 




1.1.2. Liver microscopy 
The liver lobule is formed by parenchymal and nonparenchymal cells. Hepatocytes 
and cholangiocytes are two major components of liver epithelia (Lee 2008). 
Hepatocytes (HCs), parenchymal cells, form almost 80% of the total liver volume and 
60% of the total number of liver cells. The typical hepatocyte forms a cubical cell of 15 
µm sides. Mammalian HCs are normally characterized by a polyploidy, and 30-40% of 
HCs in human adults are polyploidy (tetrapolyploid and other degrees) with dispersed 
chromatin and prominent nucleoli (Celton-Morizur et al. 2010). Hepatocyte turnover in 
the normal adult liver is slow — the life span of a HC ranges from 200 to 400 days in 
mice and rats (Malato et al. 2011). The HCs are separated from the sinusoids by the 
space of Disse. In addition, the HCs contain thousands of enzymes essential to 
perform vital metabolic functions, e.g. maintenance of glucose, amino acid, ammonia 
and bicarbonate homeostasis in the body, the synthesis of most plasma proteins, the 
storage and processing of signal molecules, bile salt excretion and, last but not least, 
they participate in the acute phase reaction (Dufour and Clavien 2005). 
Nonparenchymal liver cells, which contribute to only 6.5% to the liver volume but 40% 
of total liver cells, are localized in the sinusoidal compartment of the tissue. Of these 
cells, cholangiocytes, sinusoidal endothelial cells (SECs), Kupffer cells (KCs), hepatic 
stellate cells (HSCs, formerly called Ito cells), and natural killer lymphocytes (Kmiec 
2001). Endothelial cells, fat-storing cells, and parenchymal cells are sessile cells. In 
contrast, KCs and pit cells seem to be mobile cells and adhere to the endothelial 
lining. 
Cholangiocytes (biliary epithelial cells) are epithelial cells that line the intra- and 
extrahepatic ducts of the biliary tree (Tabibian et al. 2013). Three percent of the total 
liver mass is composed of cholangiocytes (Alpini et al. 2002). The primary 
physiological function of cholangiocytes is the modification of bile of canalicular origin 
and drainage of bile from the liver. They participate also in the detoxification of 
xenobiotics (Wise et al. 2008). Cholangiocytes are also targets in several human 
diseases including primary sclerosing cholangitis, primary biliary cirrhosis (PBC), IgG4 
autoimmune cholangitis, and may lead to cholangiocarcinoma (Lee 2008). SECs 
constitute the sinusoidal wall of the hepatic sinusoid. They perform an important 
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filtration function due to the presence of small fenestrations that allow free diffusion of 
many substances that are smaller than chylomicrons between the blood and the 
hepatocyte surface. Hepatic sinusoidal lining cells have a huge endocytic capacity for 
many ligands including glycoproteins, components of the extracellular matrix (such as 
hyaluronate and proteoglycan), immune complexes and others (Saile et al. 1999). 
They are also active in the secretion of cytokines, endothelin-1 and nitric oxide (Kmiec 
2001). SECs are vital in the development of fibrosis in chronic liver disease (Saile et 
al. 1999). 
KCs are resident macrophages, which adhere to the endothelial lining, and are 
preferentially located in the periportal sinusoids. Structurally, KCs mostly show an 
abundant clear cytoplasm which often contains lysosomes. They present as irregular 
cell coat, wormlike structures, and fuzzy-coated vacuoles (Wisse 1974). The 
intrasinusoidal localization is compatible with the pronounced endocytic and 
phagocytic capacity of tissue macrophages which are in constant contact with gut-
derived particulate materials and soluble bacterial products. Hepatic macrophages 
secrete potent mediators of the inflammatory response (reactive oxygen species 
(ROS), eicosanoids, nitric oxide, carbon monoxide, tumor necrosis factor alpha (TNF-
α), and other cytokines) and thus control the early phase of liver inflammation, playing 
an important role in the innate immune defense. Apart from typical macrophage 
activities, KCs also play an important role in the clearance of senescent and damaged 
erythrocytes (Kmiec 2001).  
1.2. Liver physiology 
The liver is considered as the largest exocrine gland, i.e. liver cells produce the bile 
which is transported via hepatic bile duct to the gallbladder and via the ductus 
choledochus to the duodenum. Liver functions arise from a collective physiology of its 
cells. The liver is central to a multitude of physiologic functions, including (Seeley et 
al. 2008):  
 Clearance of damaged red blood cells and bacteria by phagocytosis  
 Synthesis of its own proteins and secreted plasma proteins such as albumin, 
globulin, protein C, insulin-like growth factor, clotting factors etc.  
 Biotransformation of toxins, hormones and drugs  
 Detoxification of ammonia by converting it into urea 
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 Vitamin and mineral storage 
 Nutrient management involving the carbohydrate, fat and protein metabolism 
1.3. Liver pathophysiology 
There are many types of liver disease, the most common of which are viral hepatitis, 
alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), autoimmune 
hepatitis and others which may progress to cirrhosis and ultimately primary liver 
cancer. The field of interest in this study is the NAFLD. 
1.3.1. Nonalcoholic fatty liver disease (NAFLD) 
The NAFLD is a disease of globally increasing prevalence. It is defined as hepatic fat 
content exceeding 5% of liver weight (Garg and Misra 2002). NAFLD is closely 
associated with the metabolic syndrome, which consists of a constellation of insulin 
resistance (IR), central obesity (excessive fat around the abdomen), hypertension and 
dyslipidemia (Marchesini et al. 2003). For this reason, NAFLD and its progressive 
disease subtype nonalcoholic steatohepatitis (NASH) have been regarded as hepatic 
manifestation of the metabolic syndrome (Marchesini et al. 2001; Ong and Younossi 
2007). It is characterized by hepatic steatosis in the absence of a history of significant 
alcohol use or other known liver disease (Kleiner et al. 2005). Physiologically, IR is a 
condition where higher (than normal) insulin concentrations are needed to achieve 
normal metabolic responses or when normal insulin concentrations fail to achieve a 
normal metabolic response (Kahn 1978). 
To date, in the majority of patients, fatty liver is attributed either to ”excessive“ alcohol 
consumption, i.e. alcoholic fatty liver disease (AFLD), or to overweight/obesity (in 
most cases), i.e. NAFLD (Ekstedt et al. 2009). When other known causes of steatosis, 
such as certain drugs and toxins, have been excluded, the cut-off level for what is 
considered to be tolerable alcohol consumption ranging from abstinence (Diehl et al. 
1988) to, most commonly, 20 g/day, is used to differentiate between AFLD and 
NAFLD (Mccullough 2004).  
The spectrum of NAFLD ranges from simple steatosis, whereby fat is abnormally 
accumulated in hepatocytes, to NASH, fibrosis, cirrhosis, which ultimately may lead to 
hepatocellular carcinoma (Sanyal 2011). Several studies suggest that the 
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accumulation of fat in the liver is benign. However, recently it has been shown that 
fatty livers are more vulnerable to progress to the later stages of the disease (e.g. 
NASH, fibrosis) (Figure 1.2) (Adams et al. 2005). The prevalence of NAFLD rises from 
10 - 30%, while in the obese population; it is increased to 75–92% (Angulo 2002). 
Clinical relevance of NAFLD indicates that 20-30% of patients of NAFLD will develop 
NASH. Importantly, up to 20% of patients have long-standing NASH and may develop 
fibrosis, cirrhosis, or even hepatocellular carcinoma over their lifetime (Figure 1.2) 
(Adams et al. 2005; Edmison and Mccullough 2007; Ekstedt et al. 2006). Hence, on 
the basis of the U.S. population in the year 2000, an estimated 30.1 million obese 
adults in this country may have steatosis, and about 8.6 million may have 
steatohepatitis (Angulo 2002).  
1.3.1.1. Pathogenesis of NAFLD 
The nonalcohol related causes of NAFLD can be nutritional, due to drugs 
(medications), inborn metabolic disorders and others. During the 20th century, an 
extraordinary change in the pattern of caloric availability occurred in Western 
societies, which together with a more sedentary lifestyle has led to a state of chronic 
overnutrition (Neel 1999). 
1.3.1.1.1. Fat metabolism in the liver 
Dietary fats (macronutrient) are digested in the intestine and lipolytic products cross 
into the enterocyte. In the enterocytes, triglyceride (TG), cholesterol, phospholipids, 
and apolipoproteins are packaged into chylomicrons which enter the lymph system 
and then the venous circulation. The free fatty acids (FFAs) pool in the liver arises 
from hepatic de novo synthesis or from the released FFAs as a result of lipolysis in 
adipose tissue (the blood delivers these FFAs to the liver). 
Depending on the energy state, fatty acids are either stored as TG or they undergo β-
oxidation in the mitochondria or peroxisomes of the HCs. The excess fatty acids are 
converted to TG for storage or are transported into the circulation by very low density 
lipoprotein (VLDL). De novo liver lipogenesis only contributes to 8% in the feeding 
state (4% in the fasting state) of the fatty acids incorporated into the VLDL particle, 
whereas adipose tissue contributes to 44%, chylomicrons to 15%, and dietary acids to 
10% (Barrows and Parks 2006).  
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1.3.1.1.2. Accumulation of fat in the liver 
The primary metabolic abnormalities leading to TG retention in the HCs are not well 
understood, but they possibly include alterations in the uptake pathways, synthesis 
(de novo lipogenesis), degradation (β-oxidation), and/or secretion and exportation of 
the hepatic lipid resulting from IR (Charlton et al. 2002; Donnelly et al. 2005). 
1.3.1.1.3. Transition from fat accumulation into inflammation and fibrosis 
Fat accumulation in HCs has been regarded to be benign. The reason why a fatty 
liver progresses to develop inflammation and/or fibrosis, i.e. NASH, which is 
considered as the most violent form of NAFLD, is not fully understood. The 
development and progression of NAFLD to NASH occurs via a “two-hit” process 
involving the interaction of genetic and environment factors (Carmiel-Haggai et al. 
2005; Day 2002; Day and James 1998), which implicate steatosis as the first hit, 
increasing the sensitivity of the liver to secondary triggers, such as cytokines, 
mitochondrial dysfunction, lipotoxicity, oxidative stress and lipid peroxidation. IR, 
which is the main driving cause of liver steatosis, is also proposed as a transition 
factor from liver steatosis to steatohepatitis (Bugianesi et al. 2005). It induces higher 
hepatic glucose output and lipolysis, whereas steatosis is exacerbated to NASH by 
higher amounts of circulating FFAs released from white adipose tissue (Tordjman et 
al. 2008). IR and increased FFAs may both affect mitochondrial oxidation of the fatty 




Figure 1.2 Spectrum of NAFLD. Schematic of progression of the disease. Obesity, genetic factors 
and IR contribute to fat deposition in the liver. Around 30% of the patients with NAFLD have NASH 
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which involves the presence of various degrees of inflammation and fibrosis and may progress to 
cirrhosis in 20–25% within 20 years. An unknown percentage of patients will develop hepatocellular 
carcinoma (HCC) (Trauner et al. 2010). 
 
Conceptually, overnutrition in rodent models should lead to metabolic syndrome and 
liver steatosis and/or steatohepatitis, as in patients. However, in overfeeding 
conditions, rodents can adapt by modulating their intake and use of food 
(Baumgardner et al. 2008). Results from human studies indicate that patients with 
NAFLD are frequently overweight and suffer from IR. Both conditions have been 
identified to as risk factors in the development of NAFLD (Bedogni et al. 2005; 
Marchesini and Babini 2006). Furthermore, it has been suggested that the occurrence 
of NAFLD in humans is frequently associated with alteration of the intestinal barrier 
function (Miele et al. 2009). In line with these findings, results from animal models 
suggest that an increased translocation of bacterial endotoxin may induce lipid 
peroxidation in the liver, subsequently leading to an induction of TNFα (Bergheim et 
al. 2008). Furthermore, the role of the gut microbiota and other new mechanisms in 
the development of NAFLD have recently been discovered (Podrini et al. 2013). 
  
1.3.1.2. Assessment of NAFLD 
Most patients with nonalcoholic fatty liver disease have no symptoms or signs of liver 
disease at the time of diagnosis, although many patients report fatigue or malaise and 
a sensation of fullness or discomfort on the right side of the upper abdomen (Angulo 
2002). Up to 56% of NALFD patients present obesity and hepatomegaly in the 
physical examination (De Lusong et al. 2008; Paschos and Paletas 2009). Other 
reports suggest that hepatomegaly is the only physical finding in 75% of the cases, 
but it is not easy to detect it owing to the high prevalence of obesity in NAFLD patients 
(Angulo 2002). 
In general, NAFLD is linked with metabolic syndrome including visceral obesity, IR, 
type II diabetes, dyslipidemia, and hypertension (Vanni et al. 2010). Circulating 
alanine aminotransferase (ALT) and aspartate transaminase (AST) are indicative of 
hepatocyte injury and present in very low concentrations in the circulation of healthy 
individuals (Yuzer et al. 2009). On contrast, most of patients with NAFLD are usually 
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clinically asymptomatic, while their serum transaminases activities are elevated, most 
frequently serum ALT (Table 1.1) (Ekstedt et al. 2006; Yu and Keeffe 2003). 
 
Table 1.1 Noninvasive predictors of NASH in human beings (Mauss et al. 2012a) 
HAIR index (hypertension; ALT >40 U/L; insulin resistance) 
≥2 are 80% sensitive, 89% specific for NASH 
BAAT index (BMI >28; Age >50 years; ALT >2x UNL; increased TGs) 
≤1 has 100% negative predictive value for NASH 
BMI: body mass index, TG: triglycerides, UNL: upper normal limit 
 
While ultrasound, computerized tomography (CT) and magnetic resonance imaging 
(MRI) can detect liver steatosis, these methods cannot differentiate simple steatosis 
from NASH (Tarasow et al. 2002) and none of them has a capacity to detect fibrosis. 
For this reason, (percutaneous) liver biopsy remains the ”gold standard“ in the 
diagnosis of the pathology with two main limitations: technical issues (due to the 
invasive procedure) and the very limited size of the biopsy specimen with respect to 
histological heterogeneity (Bravo et al. 2001). In addition, an ethical perspective exists 
as human liver biopsy is not performed casually owing to its invasiveness. This has 
contributed to the delay in clarification of the pathological details of NASH (Semba et 
al. 2013).  
There are currently several methods available for obtaining liver tissue: percutaneous 
biopsy, laparoscopic biopsy and fine-needle aspiration. As a result of its invasive 
nature, liver biopsy can cause serious complications. In a French prospective study, 
severe complications were observed in about 0.6% of the patients (Cadranel et al. 
2000). Complications include intraperitoneal hemorrhage, mild to severe biliary 
ascites, transient bacteremia and injury of gallbladder, kidney and lungs (Bravo et al. 
2001). In addition, hospitalization due to complications resulting from a liver biopsy 
occurs in 1 - 3 % of patients. Whether the use of ultrasonography to guide the biopsy 
can lower the complication rates or may provide a higher diagnostic yield, is still 
debated (Bravo et al. 2001). 
Ultrasonography of the liver is safe and relatively inexpensive (Torres and Harrison 
2008). Fatty infiltration of the liver produces an increased echogenicity when 
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compared to the echogenicity of the kidneys. The increased echogenicity is due to the 
fact that fat attenuates ultrasound more than normal liver parenchyma (Quinn and 
Gosink 1985). Therefore, when used in prevalence studies, ultrasonography 
underestimates the prevalence of fatty liver (Saadeh et al. 2002). Interestingly, there 
is a noninvasive marker to assess the fibrosis: fibroscan and (transient) elastography. 
It works like ultrasound and gives a number for determining a fibrotic score (Sandrin 
et al. 2003). 
1.3.1.3. Histopathology of NAFLD 
Histologically, steatosis is defined as an increase of fat content in hepatocytes (Attar 
and Van Thiel 2013). There are different scores or grades of steatosis assessed in 
liver biopsies via a morphological semiquantitative approach. For example, the degree 
of fatty infiltration in NAFLD is graded according to the percentage of HCs with fat 
deposits: mild steatosis involves less than 30% HCs, moderate NAFLD up to 60%, 
and severe NAFLD above 60% (Ploeg et al. 1993). It has been suggested that < 5% 
of HCs involved should be considered normal (Adams and Angulo 2005). 
In the case of NASH, the first histological criterion is liver steatosis (usually 
macrovesicular and centrilobular). The second is hepatocellular ballooning, 
characterized by enlarged swollen HCs, with reticulated cytoplasm, denoting cellular 
injury with cytoskeleton alterations (Lackner et al. 2008). Ballooned cells are the most 
characteristic feature of necroinflammation and hepatocellular injury in NAFLD, and 
they are often associated with steatotic perivenular HCs. Importantly, hepatocellular 
ballooning is considered a key feature of the evolution from simple steatosis to NASH 
and cirrhosis (Brunt et al. 2004). The third feature involves lobular inflammation which 
is usually mild and composed of mononuclear or polymorphonuclear neutrophil (PMN) 
cells (or both). As the disease progresses, liver fibrosis may develop (Kleiner et al. 
2005) (Table 1.2). Mallory bodies are occasionally seen but are not necessary for the 
diagnosis. The presence of these features, alone or in combination, accounts for the 
wide spectrum of NAFLD (Angulo 2002). A finding of fibrosis in NAFLD suggests 
more advanced and severe liver injury (Angulo 2002), while steatosis and 
hepatocellular ballooning regress as the fibrosis stage progresses. In some patients 
with cirrhosis, the features of steatosis and necroinflammatory activity may no longer 
be present (Bacon et al. 1994). 
 




Table 1.2 NAFLD, histological classification/changes (Tilg 2004). 
1. NAFL (nonalcoholic fatty liver) 
Simple steatosis  Type 1; simple fatty liver 
NASH Type 2; predominantly macrovesicular steatosis, lobular inflammation  
 Type 3; additional ballooning degeneration (dying enlarged hepatocytes) 
 Type 4; in addition Mallory bodies (rather periportal) fibrosis 
2. AFL (alcoholic fatty liver) 
 Ballooning degeneration (enlarged dying hepatocytes) 
 Prominent infiltrate with neutrophils (rather located at Mallory bodies) 
 Necrotic hepatocytes, focal  
 Mallory bodies (rather perivenular) 
 
1.3.1.4. Treatment 
Moderate weight loss as a result of dietary and life-style modifications is the only 
therapy proven to be effective in NAFLD. Complete alcohol abstinence and good 
control of diabetes mellitus are probably also important to reduce the risk of severe 
liver disease in NASH (Mauss et al. 2012). Vitamin E, metformin, rosiglitazone and 
lipid-lowering agents (e.g. statin (Merat et al. 2003)) have yielded promising results, 
such as improvement in values of the liver-tests as well as histological findings in the 
patients. However, these medications require further evaluation in carefully controlled 
clinical trials (Angulo 2002). Avoiding the extensive consumption of fast food and 
fructose-enriched foods and more physical exercises are some recommendations 
given to lessen the disease occurrence. 
1.3.1.5. Animal models for NAFLD 
Various animal models have been established to investigate the disease. Existing 
models of NAFLD/NASH have several disadvantages in the reproduction of complete 
features of NAFLD when compared to humans. For example, a possible model of 
steatohepatitis induction (with or without fibrosis) failed to provide features of the 
metabolic syndrome. In contrast, reproduction of the metabolic syndrome was 
successful, yet with incomplete histological features of NASH (Charlton et al. 2011). 
Although there are small animal platforms that summarize some of the histological 
features of simple steatosis, only some of them are NASH models with consistent 
hepatocellular ballooning and progressive fibrosis, physiologically reproducing a 
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metabolic profile of the human condition (Charlton et al. 2011). Thus, a representative 
model is required to study the pathogenesis of NAFLD, specifically the progression 
from simple steatosis to NASH. 
Of the genetically engineered models, the obese Zucker fatty rat (ZF fa/fa), whose 
defective leptin receptor leads to a poor binding affinity for its ligand, develops 
obesity, hyperphagia, IR and hypertriglyceridemia (Gary-Bobo et al. 2007). A more 
recent overnutrition-based model like the fast food diet mouse model has 
demonstrated substantial metabolic similarity to humans with NAFLD type I and 
NASH, but it incompletely reproduces the histological features of NASH (Shiri-
Sverdlov et al. 2006). For instance, no macrosteatosis, HCs ballooning, or fibrosis 
were not found, instead only CD68+ cells were present in the liver tissues. The ob/ob 
mouse develops obesity but it is leptin-deficient and lacks the inflammatory and 
fibrosis components of NASH (Leclercq et al. 2002). Furthermore, a model of a high-
fat diet in male C57BL/6J mice led to the development of features of the metabolic 
syndrome and steatohepatitis but only mild fibrosis after 50 wks (Ito et al. 2007). The 
methionine and choline deficient diet was also used to induce NASH in C57BL/6 mice. 
This model, however, does not mimic human physiological condition, and the 
metabolic profile is opposite to the typical features of human NASH, as well 
(Takahashi et al. 2012).    
The addition of fructose to a diet high in saturated fat and cholesterol has been 
proposed to reproduce all of the features of NASH, including ballooning in large 
animals, which is also a typical feature of the diet of humans with NASH (Charlton et 
al. 2011). However, LCN2 was not investigated in that study. Since fructose is 
included in commercial/fast food as well as juice beverages and as it has been 
suggested to induce the most NAFLD manifestations noticed in humans, this study 
selected fructose as an inducer for metabolic syndrome and NAFLD. 
1.4. Fructose 
1.4.1. Definition 
D-fructose is a simple sugar (monosaccharide) found naturally in fruit, honey, 
sucrose, and vegetables. Normally, it is metabolized in HCs into glucose, glycogen, 
and lipid. Industrially, fructose is frequently found in soft drinks, juice beverages, and it 
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is integrated into convenient pre-packaged foods (Akar et al. 2012). The five-ring 




Figure 1.3 The cyclic (5-ring) structure of D-fructose according to IUPAC. 
 
1.4.2. Fructose metabolism 
Fructose is transported from the small intestine (enterocytes) via a specific glucose 
transporter, GLUT5 and exits actively or facilitated (or both) via GLUT2 and GLUT5 
transporters (Wiernsperger et al. 2010). Upon intestinal absorption, both fructose and 
glucose are delivered via the portal vein to the liver. It is believed that the ability of the 
liver to metabolize high doses of fructose is responsible for the disruption in energy 
stores and fuel metabolism (Commerford et al. 2002; Daly et al. 1997). There are 
marked variations in estimates of blood fructose concentrations arising from 
differences in methods of collection and analysis (Douard and Ferraris 2008). Serum 
fructose concentration was estimated to be 0.008 mM in normal humans, while 
plasma fructose was 0.030 mM. These variations can also arise from differences in 
fructose consumption, which is a potent regulator of intestinal fructose transport 
(Douard and Ferraris 2008). 
In contrast to glucose, the phosphorylated product, fructose 1-P, is directly 
metabolized into glyceraldehyde and dihydroxyacetone phosphate by aldolase B (EC 
4.1.2.13) independent of insulin. Thus, fructose can then readily converge with the 
glycolytic/gluconeogenic pathways at the level of triose phosphate (Van Den Berghe 
1986) (Figure 1.4). Fructose catabolism is able to by-pass the main regulatory step of 
glycolysis: the conversion of glucose 6-P to fructose 1,6P2, controlled by 
phosphofructokinase (EC 2.7.1.11). Hence, while the glucose metabolism is 
negatively regulated by phosphofructokinase, which, in turn, is allosterically inhibited 
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by high ATP and citrate levels in the cell, fructose can continuously enter the 
glycolytic pathway at C3 metabolism level. Therefore, fructose can uncontrollably 
generate glucose, glycogen, lactate, pyruvate and provides both the glycerol and acyl 
portions of fat. In certain conditions, glucose formation resulting from fructose may 
compete with the fructolysis process. 
 
 
Figure 1.4 Utilization of fructose and glucose in the liver. P, phosphate, TG, triglyceride. The 
hepatic fructose metabolism begins with phosphorylation by fructokinase (EC 2.7.1.4). The fructose 
carbon enters the glycolytic pathway at the triose phosphate level (dihydroxyacetone phosphate and 
glyceraldehyde-3-phosphate). Thus, fructose bypasses the major control point by which the glucose 
carbon enters glycolysis (phosphofructokinase), where the glucose metabolism is limited by feedback 
inhibition by citrate and ATP. This allows fructose to serve as an unregulated source of both glycerol-3-
phosphate and acetyl-CoA for hepatic lipogenesis (Elliott et al. 2002).  
 
1.4.3. Fructose and liver diseases 
There is strong evidence that diet affects the development of NAFLD (Le and 
Bortolotti 2008). Recently, since the increase of fructose utilization in the commercial 
food industry accompanies the global increase in health troubles, distinct studies have 
correlated dietary fructose intake with the prevalent metabolic syndrome and obesity-
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associated diseases such as type 2 diabetes and fatty liver (Bantle 2009). The 
exposure of the liver to large quantities of fructose (to date 85–100 grams per day) 
leads to rapid stimulation of lipogenesis and TG accumulation. The latter may 
contribute in reduced insulin sensitivity and hepatic IR. Increased fructose 
consumption is associated with fibrosis severity in patients with NAFLD (Abdelmalek 
et al. 2010). 
Moreover, previous studies stated that a chronic fructose intake may, at least partly, 
contribute to the development of the early phase of NAFLD (Cummings 1988) through 
mechanisms involving intestinal bacterial overgrowth and/or an increased intestinal 
permeability and translocation of bacterial endotoxin, and subsequent activation of 
KCs through a TLR-4-dependent mechanism mediated through MyD88-dependent 
signaling pathways (Brun et al. 2007; Cani et al. 2008). Specifically, it has been 
shown that MyD88 (an adapter protein involved in the Toll-like receptor signaling 
pathway in the innate immune response) is involved in the rapid activation of nuclear 
factor B (NFB) and the consequent increase of TNF-α (Velayudham et al. 2009). This 
leads to an increased formation of ROS (Zimmet et al. 2001) through its entering the 
cellular metabolism independent of insulin and results in increased de novo lipogensis 
(Spruss et al. 2009). Protection of the intestinal epithelial cells against the loss of tight 
junction proteins (e.g. occludin), resulting either from direct or indirect effects of the 
chronic intake of fructose on the intestinal mucosa, seems to be a key factor (Volynets 
et al. 2010). It has been shown that bile acids may protect the liver from the onset of 
NAFLD. 
A typical feature of fructose is the induction of hypertriglyceridemia. This is remarkably 
because of reduced clearance (Wiernsperger et al. 2010) accompanied with IR. In 
addition to its effects on TGs, fructose also decreases high density lipoprotein-bound 
cholesterol (HDL-C) levels (Wiernsperger et al. 2010). Furthermore, diets specifically 
high in fructose have been shown to contribute to a metabolic disturbance in animal 
models resulting in weight gain and hyperlipidemia (Kasim-Karakas et al. 1996). 
1.4.4. Fructose and oxidative stress and lipid peroxidation 
Unlike glucose, which is widely used by tissues throughout the body, fructose is 
primarily metabolized in the liver and it facilitates oxidative damage and lipid 
peroxidation (Anurag and Anuradha 2002), a process in which unsaturated lipids 
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become oxidatively degraded to a variety of products at sites of inflammation. The 
degradation of lipids occurs, whereby free ROS capture electrons from lipids in cell 
membranes. One of the end products of lipid peroxidation is 4-hydroxynonenal (4-
HNE), a specific, stable, and highly reactive product, which exhibits a chemotactic 
activity toward neutrophils in vitro and in vivo (Quinn et al. 1995). Apoptosis is also 
induced by the products of lipid peroxidation (Ribeiro et al. 2004). In mice, a chronic 
moderate fructose intake (e.g. 30% fructose solution as only fluid source) was shown 
to be associated with an increased translocation of lipopolysaccharide (LPS, 
endotoxin) from the intestine into the portal vein as a result of bacterial overgrowth 
and increased intestinal permeability. This may cause a further activation of hepatic 
Kupffer cells and formation of ROS in the liver and an NF-κB-dependent induction of 
hepatic TNF-α expression (Spruss et al. 2009). 
The metabolic process produces acetaldehyde, a toxic and reactive compound that 
impairs mitochondrial function leading to increases in ROS production (Dey and 
Cederbaum 2006). ROS is important for certain cellular functions, e.g. it can be 
cytotoxic to foreign bacteria (Arteel 2003). In addition, ROS production is detrimental 
when excessive amounts are produced leading to tissue damage. ROS can act as a 
second messenger and induce apoptosis, in part, by signaling through the mitogen-
activated protein kinase (MAPK) pathway (Lu et al. 2007). Increases in ROS 
production also cause necrotic cell death by depleting endogenous antioxidants (Wu 
and Cederbaum 2001). Oxidative stress and 4-HNE induce apoptosis in HSCs by 
increasing the expression of apoptotic regulatory proteins and adaptors, such as Fas 
ligand and FasL receptor, caspase-2 (casp 2), casp 3 and Bax (De Villiers et al. 
2007). Apoptosis, also known as programmed cell death, is a cascade of reactions 
culminating in a non-inflammatory elimination of a cell without disrupting the 
surrounding tissue and maintaining homeostasis (Henson and Hume 2006). 
1.5. Lipocalin-2 
1.5.1. Definition 
Previous reports studied the role of lipocalin-2 (LCN2) in inflammation and in 
metabolic syndrome. LCN2, a neutrophil gelatinase–associated lipocalin (NGAL), is a 
member of the lipocalin subfamily (25-kDa) known as secretory glycoprotein initially 
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identified from human neutrophils (Chen et al. 2005) and cells and tissues that are 
exposed to microorganisms e.g. the gastrointestinal tract (Cowland and Borregaard 
1997). The lipocalin family in general plays the role of transporters with various 
functions, e.g. regulation of immune responses (Yang et al. 2002). By forming a cup-
shaped hydrophobic cavity; lipocalins bind and transport a wide variety of small 
lipophilic substances, such as retinoids, arachidonic acid, iron, lipids and various 
steroids (Flower 1996). 
In addition, LCN2 (Figure 1.5) is a pleiotropic protein which presents abundantly in the 
circulation, and it has also been detected in adipocytes and macrophages (Zhang et 
al. 2008). Immunologically, LCN2 plays a key role in implementing the acute-phase 
response (Liu and Nilsen-Hamilton 1995), and it also has a role in the regulation of 
apoptosis (Devireddy et al. 2001). It was demonstrated that the liver is the main 
source of serum LCN2, which is highly expressed in the turpentine-oil model 
(Borkham-Kamphorst et al. 2011; Sultan et al. 2013; Sultan et al. 2012). It preferably 
binds to lipophilic substances and plays a role in iron metabolism, regulates 
hematopoiesis, modulates inflammatory processes and restoration of tissue 
homeostasis following LPS-induced injury (Borkham-Kamphorst et al. 2011). 
 
   
Figure 1.5 Lipocalin/ cytosolic fatty-acid binding protein family (www.ncRNA.org (rat gene Lcn2 
(X13295) description and page index)). 
 
Interestingly, LCN2 has been characterized as a critical regulator of energy 
metabolism, glucose and lipid homeostasis, and IR in Lcn2-deficient mice (Guo et al. 
2010). It has also been reported that LCN2 suppression attenuates obesity-induced 
IR by modulating 12-lipoxygenase and TNF-α levels in adipose tissue (Law et al. 
2010). In humans, elevated serum LCN2 concentration was also observed among 
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diabetic patients and this increase could be reversed by the insulin-sensitizing drug 
rosiglitazone (Wang et al. 2007). Recent research showed that LCN2 was provoked in 
a rat model after in vivo liver γ-irradiation in response to the development of ROS 
(Sultan et al. 2013). 
LCN2 has also been shown to be a bacteriostatic agent capable of binding iron in the 
form of siderophores by a non-heme compound which consequently sequesters it 
from inflammation and infection sites (Berger et al. 2006; Flo et al. 2004). Promoter 
regions of Lcn2 and its murine homolog 24p3 have been found to contain consensus 
sequences for several different transcription factors, including NF-kB, C/EBP and 
cAMP response element-binding protein (CREB) (Cowland et al. 2006). 
1.5.2. LCN2, oxidative stress and lipid peroxidation 
Increased Lcn2 gene expression has been found in oxidative stress induced by 
chemicals such as diethylnitrosamine, which is a major producer of ROS (Lechner et 
al. 2001). Several studies have reported an LCN2 expression under stress conditions 
to be caused by free radicals, such as inflammation, toxicity, chronic kidney disease, 
myocardial infarction and burn injury, infections and several types of cancers (Mishra 
et al. 2006). In the absence of cellular stress, LCN2 maintains a low steady-state level 
and exerts very little if any effect on the fate of tissue (Sultan et al. 2012). Lcn2 gene 
expression has been studied both in Lcn2-/- models and in several NAFLD models, 
such as ob/ob and db/db (Jin et al. 2011; Jun et al. 2011; Law et al. 2010; Wang et al. 
2007). While an important role for Lcn2 gene expression in inflammatory and glucose 
metabolism processes could be identified, LCN2 was not previously evaluated in 
(high)fructose induced NASH. In addition, LCN2 protein localization in the cell 
population of the liver is controversially discussed, and the LCN2-expressing cell type 
in the liver is still being debated. 
1.5.3. LCN2 receptor 
The LCN2/NGAL/24p3 receptor (24p3-R) is poorly understood and incompletely 
identified in the liver to date. In rodent distal nephron, the 24p3-R is expressed where 
it mediates protein endocytosis (Langelueddecke et al. 2013). Therefore, state-of-the-
art methods are urgently required to pursue and understand the function and 
localization of LCN2 in the liver. 
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1.6. Study Motivations 
While ultrasonography, CT scan and MRI are reliable and sensitive methods for 
detecting steatosis, but the grade and stage of the disease can be determined only 
with a liver biopsy (Angulo 2007). Instead, liver biopsy is needed to detect the switch 
from simple steatosis to NASH. However, this is an invasive (puncture) procedure 
with a risk of bleeding and injury to gallbladder, lungs and kidney. Thus, research for 
noninvasive (serological) diagnostic markers is required. The pathogenesis of NAFLD 
remains unknown. Lcn2 gene expression has been studied in Lcn2-/- models and in 
several NAFLD models, such as db/db, ob/ob, ZF fa/fa, etc. which do not greatly 
mimic the physiological and/or histological features of NAFLD seen in humans. In 
addition, the following technical aspects have to be taken into account prior to 
establishing a suitable animal model: 
 Reproducibility. 
 Commercial availability. 
 Time schedule and feeding in accordance with animal welfare. 
 Costs. 
 The food composition. 
Some of the available animal models showed the feature of NAFLD after 50 wks. 
Hence, there is a need for an animal model that mimics the condition seen in human 
NAFLD and fits with these technical aspects. 
Since fructose is included in commercial/fast food and juice beverages and as it was 
suggested to form most of the NAFLD manifestations noted in humans, fructose was 
selected as an inducer for metabolic syndrome and NAFL (>type 2) in this study. 
LCN2 is a known positive acute phase protein, which is synthesized in stress 
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1.7. Research Hypotheses and Aims 
The present study focused on the liver as it plays a pivotal role in inflammation and 
the homeostasis of lipid, carbohydrate and other metabolisms. NAFLD is a metabolic 
liver disease with increasing prevalence. The availability of more representative and 
differentiated NAFLD models could greatly facilitate studies on the pathobiology of 
different NAFLD types, such as simple steatosis and NASH, as well as investigations 
on potential interventions to avoid the latest stages of the disease. 
Hypotheses 
1. Conditions of low physical activity and overnutrition with a high caloric intake of 
35% kcal fat could lead to simple steatosis. 
2. Chronic feeding of rats with a fructose-enriched diet will lead to NASH which 
might be similar to the physiological milieu seen in humans. 
3. Fructose-caused oxidative stress and inflammation could trigger hepatic LCN2 
expression in nutritionally induced rat fatty liver. 
4. LCN2 may serve as a biomarker for NASH. 
The aims of the present study are 
i. to develop simple steatosis and NASH models 
ii. to compare the features of these models with what is known about the human 
liver pathology and other NAFLD parameters 
iii. to explore and compare the expression of LCN2 and other parameters in these 
models, and to assess whether LCN2 may serve as a diagnostic indicator for 
NASH. 
iv. to investigate the potential mechanism(s) of the production and possible role(s) 
of LCN2 in currently studied models.  
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2. MATERIALS AND METHODS 
2.1. Materials 
2.1.1. Chemicals 
The chemicals that were used in this study are listed in Table 2.1. 
 
Table 2.1 List of the chemicals and materials that were used in this study. 
Provider Chemical 
Applichem, Darmstadt, Germany 3-[(3-Cholamidopropyl)-dimethylammonio]-1-
propanesulfonate (CHAPS), Glycine, 
Methanol, Glacial acetic acid, Acetonitrile 
Carl Roth GmbH & Co. KG, Karlsruhe, Germany Bromophenol blue, Glycerine, Tris, Sodium 
choloride, Sodium acetate, Sodium hydroxide 
Sigma-Aldrich Chemie, Hamburg, Germany Urea, Thiourea, DL-Dithiothreitol 
(DDT),Phenylmethylsulfonyl fluoride (PMSF), 
HEPES sodium salt, Nile red, Sodium dodecyl 
sulphate (SDS), Tritin-X 100, Nonidet NP-40 
Merck KGaA, Darmstadt, Germany Phosphatase inhibitor cocktail 1 and 2, 
Iodoacetamide, Sodium acetate, Ethanol, 
Formaldehyde, Sodium carbonate, β-
mercaptoethanol, Kaiser’s glycerol gelatine, 
Mayer’s Hemalum solution, AQUATEX 




Immobilized pH gradient strip (IPG), 
Phosphate buffered saline (PBS), Bio Rad 
protein assay kit, Tween 20 
Serva Electrophoresis GmbH, Heidelberg, 
Germany 
Bis/acrylamid, 2 mg/mL Albumin bovine 
Fraction V, Ponceau S 
Bio-Rad, USA Mineral oil 
Invitrogen, Ltd., Paisley, UK Pro-Q
®
 Diamond Phosphoprotein Gel Stain 
Platinum SYBR
®
 Green Universal qPCR 
Master Mix (Applied Biosystems
®
) 
Reverse Transcriptase (RT) and 1x RT buffer 




 Novex 4-12% Bis-Tris Gels 
Rainbow
TM
 coloured-protein marker 
Percoll-gradient solution 
Merial GmbH, Hallbergmoos, Germany Pentobarbital sodium (Narcoren®) 
anaesthesia 
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Millipore, MA. USA Accutase, Leptin, Radioimmunoassay (RIA) kit 
Lonza Braine SA, Braine-l’Alleud, Belgien Penicillin/streptomycin, RPMI 
BioAssay Systems, EnzyChrom TM Kit, Hayward, 
USA 
Triglyceride (TG) assay 
Bioporto® immunoassay kit, Denmark LCN2 ELISA 
Amersham Biosciences, UK Ficoll-Pague
TM
 PLUS 
Biochrom, Berlin, Germany Trypan blue 
 
2.1.2. Equipment 
The technical equipment (apparatus) and the companies were listed in Table 2.2. 
 
Table 2.2 The technical equipment that were utilized in this study. 
Application Manufacturer 
2-DE gel scanner FLA-8000, Fujifilm Europe, Düsseldorf, Germany 
Tissue culture cabinet: clean air Thermo life science, Lund, Sweden 
Microplate reader Dynatech MRX, Cottbus, Germany 
Homogenizer and Tissuelyser Ultra-Turrax ®,Janke & Kunkel IKA, Staufen, Germany 
Sonicator Branson Sonifier 250, Branson, USA 
Microplate/Support Base Applied Biosystems® StepOne system, MicroAmp™, 
Darmstadt, Germany 
Epifluorescence microscope 
IDO3, Standard 25, Axiovert 200M 
Zeiss, Göttingen, Germany 
Film processor machine Konica SRX-101A, Japan 
Centrifuge Mikro Rapid 
Centrifuge K, Rotixa  
Hettich, Tuttligen, Germany 
Sigma, Osterode am Harz, Germany 
pH-Meter CG841 Schott, Mainz, Germany 
PROTEAN IEF Cell first dimensional IEF Bio-Rad, Munich, Germany  
Protean II xi Cell, 2-DE gel 
electrophoresis 
Bio-Rad, Munich, Germany 
Gel dryer Model 583, Bio-Rad 
Western blot apparatus: XCell 
SureLock® Mini-Cell system 
Invitrogen, Ltd., Paisley, UK 
Light microscope (with an internal digital 
camera) 
Olympus BX43, Hamburg, Germany (Olympus DP21) 
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The antibodies that were used for Western blotting (WB) and immunofluorescence 
(IF) staining are listed in Table 2.3. 
 
Table 2.3 List of the antibodies that were used in this study. 
Name Clone Species Company dilution Use 
HNE PC Rabbit Abcam 1:100 WB 
LCN2 MC Mouse Novus biologicals 1:250 WB 
 PC Goat R&D 1:100 IF 
GRP-78 PC Rabbit Novus Biocompa 1:800 WB 
CD14 PC Rabbit Antibodies-online 1:700 WB 
Casp 9 PC Rabbit Chemicon 
international 
1:1200 WB 
Cyt c MC Mouse Millipore 1:600 WB 
PGC-1α PC Goat Abcam 1:200 WB 
IκB1α MC Rabbit Abcam 1:10000 WB 
β-actin MC Mouse Sigma-Aldrich 1:5000 WB 
MPO PC Rabbit Dako, A0398 1:100 IF 
ED1 MC Mouse AbD Serotec 1:100 IF 
Anti-rabbit-HRP PC Swine Dako 1:1500 WB 
Anti-mouse-HRP PC Rabbit Dako 1:1500 WB 
AlexaFluor-555-Conjugated 
anti-goat IgG 
 Donkey  Invitrogen 1:500 IF 
AlexaFluor-488 conjugated 
anti-mouse or anti-rabbit IgG 
 Donkey  Invitrogen 1:500 IF 
MC: monoclonal, PC: polyclonal, HRP: horseradish peroxidase 
2.1.4. Oligonucleotides 
The forward and reverse primers for the quantification of the rat mRNA expression of 
the genes by quantitative Reverse-Transcription Polymerase Chain Reaction (qRT-
PCR) listed are shown in Table 2.4. 
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The following scientific software (Table 2.5) was applied for data acquisition and 
analysis. 
 
Table 2.5 List of the scientific software that were applied in this study. 
Software Application  Reference 
StepOne
TM
 Version 2.0 RT-PCR Applied Biosystems®, 
Darmstadt, Germany 
GraphPad Prism 5 Statistical analysis GraphPad Software Inc. 
California, USA 
AxioVision Rel. 4.8 Histo-localization analysis Carl Zeiss, Jena, Germany 
ImageJ 1.46s Densitometric analysis NIH, MD, USA 
Reference Manager 12 
EndNote 
Insert the desired References for 
in-Text citations and format the 
bibliography at a later time 
Thomson Reuters, New 
York, USA 
Delta2D V 4.2 Analysis of 2-DE data Decodon, Greifswald, 
Germany 
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2.2.1. Experimental animals and diets 
Healthy male Sprague-Dawley rats (160-180 g) were used in this study. All animals 
were purchased from Charles River, Sulzfeld, Germany. On arrival at our facility, the 
rats were placed immediately in their respective experimental conditions. For house 
acclimatization, the rats were provided with standard chow diet and tap water for one 
week ad libitum. To facilitate measures of food intake and to promote minimal 
sedentary movement patterns, the rats were maintained individually in conventional 
cages in a 12:12 h light-dark cycle in a hygienically controlled room. Ethically, all 
animals received humane care within the provision of the German Law on the 
Protection of Animals and the institutional guidelines. All animal experiments were 
approved by the ethics review board and supervised by the local ethics commission 
(Application # 33.9-42502-04-10/0152). 
2.2.2. Fructose-containing Lieber-DeCarli diet 
The Lieber-DeCarli (LDC) diet is a nutritionally complete liquid diet that is used widely 
for modeling (in rodents) the pathological changes seen in human beings (Cohen et 
al. 2009). The standard diet composition for rats on the LDC diet is (in kcal) 35% fat, 
17% protein, and 48% carbohydrates (Lieber and Decarli 1994). The carbohydrate 
source in the LDC diet is maltodextrin, while the amount of calories provided by fat is 
similar to that found in the typical American diet. As the amount of energy that is 
provided by 1 g of the LDC diet is known, about 70% kcal fructose was mixed with 
LDC powder, and this group was named the LDC + high fructose (L-HFr) group. Each 
gram of both diet categories was calibrated to provide approximately (one) energy 
unit. 
2.2.3. Induction of nonalcoholic fatty liver in rats 
Animals were randomly allocated (n= 4 per group/ time point) as follows: standard 
chow pellets (control (Co)) group, liquid Lieber-DeCarli (LDC) group, also called high-
fat diet, and LDC + high (70%) fructose (L-HFr) group (Figure 2.1). Apart from the Co 
group, the animals did not receive additional drinking water as the liquid diets were 
sufficient (Wang et al. 2008). The animals were allowed access to a pre-weighed 
amount of food for 4 wks or 8 wks. The amounts of the consumed food were recorded 
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daily, while animal body weights (BW) were measured weekly throughout the study. 
The animals were deprived of any food 10 h before sacrifice. 
 
 
Figure 2.1 Diet categories and feeding periods. 
 
2.2.4. Collection of blood and liver samples 
After 4 wks or 8 wks, the animals were weighed and euthanized using sodium 
pentobarbital (Narcoren ®) (0.2 mL per 100 g BW i.p.). Under deep anesthesia, the 
rats were subjected to laparotomy, photographed, and blood was withdrawn from the 
inferior vena cava in plain (sera) and heparinized plasma tubes. Subsequently, livers 
were excised, weighed, photographed, and quickly dipped in physiological saline. 
Next, three portions of different liver lobes of each animal were immersion-fixed (with 
4:1% (v/v) neutral-buffered formaldehyde: glutaraldehyde in isotonic PBS, pH 7.4) for 
paraffin embedding. Alternatively, liver pieces were snap-frozen in liquid nitrogen and 
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stored at -80°C until use. Relative liver weights (RLW) were expressed as a 
percentage of the ratio of absolute liver weight in gram, divided by the total body 
weight (g) at the time of sacrifice multiplied by 100. 
 
2.2.5. Histological (morphological) staining 
2.2.5.1. Oil Red O 
2.2.5.1.1. Principle 
It is a diazo dye targets to stain the accumulated lipids (within the cells) which include 
fats, sterols, fat-soluble vitamins, monoglycerides, diglycerides, phospholipids, 
lipoproteins and others. 
2.2.5.1.2. Solutions’ preparation 
Preparation of Oil Red O stock solution 
The Oil Red O stock solution was prepared in a concentration of 5 mg/mL Oil Red O 
powder/ isopropanol with a magnetic shaking. This solution is stable at RT for about 3 
wks. 
Preparation of working solution 
A 60% working solution was prepared by dilution of the stock solution with dH2O. The 
solution was then double filtrated 1 h at RT. 
PBS pH 7.4 buffer: 137 mmol/L sodium chloride, 2.7 mmol/L potassium chloride, 10 
mmol/L disodium hydrogen phosphate, 1.76 mmol/L potassium. 
2.2.5.1.3. Oil Red O staining procedure 
Tissue preparation 
To determine cellular lipid accumulation, liver tissue portions were fixed with 4% 
phosphate-buffered 4:1% formalin/glutaraldehyde for 15-20 minutes (min) at 4°C, 
washed for 5 min in PBS, and immersed in 10% fresh-buffered sucrose for 2-3 h and 
in 30% sucrose overnight. The hepatic pieces were embedded in an optimal cutting 
temperature medium-filled aluminum foil mold, and were successively frozen at -20°C. 
Staining recipe 
Liver cryosections (5 µm) were prepared from OCT-embedding medium, and stained 
with filtered Oil Red O working solution for 30 min at RT. Afterwards, the slides were 
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washed 3 times with ddH2O, and nuclei were counterstained with hematoxylin (Mayer’s 
Hemalum solution) for 1-2 min. Then, twice washing steps were performed by using 
tap H2O; the slides were immediately mounted with AQUATEX, allowed to dry and 
finally photographed by light microscope with a build-in camera. 
2.2.5.2. Fluorescence-based Nile red staining 
Epi-fluorescence microscopy is a technique that is used in the evaluation of 
fluorochrome-stained samples. As Nile red and immunofluorescence stains are based 
on the use of fluorescent substances, it is useful to explain the fluorescence principle 
briefly. 
Fluorescence is a special form of luminescence, in which a photon of the same or 
lower energy is emitted while the molecule is returning to the ground state. A (color) 
substance that is able to fluoresce is called a fluorochrome. These fluorochromes 
have often in their structure an aromatic ring group, and they can be used to ‘‘mark’’ 
or label the desired substance, e.g. an antibody. Fluorescent dyes absorb light at 
certain wavelengths (λ) e.g. ultraviolet or blue and in turn emit their fluorescence 
energy at a longer λ, e.g. green or red. This difference in excitation and emission 
maxima of a fluorescent dye is called Stoke’s shift, which represents the basis for 
fluorescence detection. As each dye has almost a distinct emission spectrum, this 
prosperity can be exploited for multicolor analysis using several fluorochromes 
simultaneously. 
Fluorescence results only in a very short visible or measurable emission of light 
quanta, while phosphorescence can gradually release the absorbed energy over time 
in the visible band after excitation. The electrons return from the excited state (S1) to 
the original energy state (S0) very fast (10-9 sec). On the other hand, the 
phosphorescence occurs when the emission delays (lags) of min to days to S0 state. 
The Jablonski diagram (Figure 2.2) shows the number of possible routes by which an 
excited molecule can return to its ground via unstable triplet states. A rapid return 
results in fluorescence, while a delayed return leads phosphorescence. 
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Figure 2.2 Simplified Jablonski diagram. The chain of events that lead to fluorescence and 
phosphorescence are shown. S0 is the ground state; T1 is an excited triplet state, S1 and S2 are 
excited singlet states. Straight lines represent transitions involving photons, while waved lines 
represent vibrational or thermal transitions (Nery et al. 2010). 
 
2.2.5.2.1. Nile red staining protocol 
Fluorescent Nile red dye, 9-diethylamino-5H-benzo[α]phenoxazine-5-one, is an 
excellent vital and selective stain for the detection of intracellular neutral lipid droplets 
(e.g. TG) by fluorescence microscopy (Greenspan et al. 1985). Nile red does not 
fluoresce in aqueous or polar solutions; in contrast, it is very soluble in hydrophobic 
phases and excites at λ 450-560 nm, while the emission is detected at λ= 590 nm. 
Hepatic cryosections (5 µm) were stained with 4,6-diamidino-2-phenylindole (DAPI) 
(Molecular Probes) for 5 min, washed for 5 min with PBS. A mixture of 750 μl of 65°C 
heated-Kaiser’s glycerol gelatin, 250 μL ddH2O and 50 μL of light-protected Nile red 
solution was added per 4 slides. Afterwards, sections were cover-slipped and allowed 
to shortly dry in dark, followed by fluorescence-immunodetection using an 
epifluorescence microscope. Microphotographs were collected accordingly. 
2.2.5.3. Haematoxylin and eosin stain 
Morphological changes of the liver were histologically evaluated via Haematoxylin and 
eosin (HE) stain. The stained liver tissues were examined for inflammation and fat 
degeneration. Paraffin-embedded hepatic slices of 5 μm thickness were transversely 
cut into serial sections by a microtome. Sections were deparaffinized in xylene 2x (3 
min), rehydrated through a graded ethanol series (100%, 96%, 80%, & 60%) and 
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stained automatically with haematoxylin (6 min). Subsequently, the slides were placed 
for 5 min under running tap water, counterstained for 2 min with eosin and washed 
with water. The slides were again dehydrated by immersing in ascending ethanol 
gradients, and finally placed in xylene until mounting. Afterwards, the slides were 
mounted with xylene-based media and air-dried. 
The nuclei were stained blue-purple with hematoxylin, while cell cytoplasms (proteins) 
were nonspecifically counterstained with pink-red (eosin). A pathologist (Schaefer IM) 
who had no knowledge about the rats’ treatments carried out the histological 
examination. In addition, the HE stained slides were evaluated by three different 
scientists by using a light microscope with an internal digital camera. 
2.2.5.4. Masson’s Trichrome stain 
Masson’s stain was used for different specific applications such as distinguishing cells 
from surrounding connective tissue (collagen, fibrosis, and architectural changes of 
liver sections). Five micrometer liver sections were used for this staining. The 
procedure was done according to the manufacturer’s  instructions. The diagnostic 
criteria of the fibrosis stages applied by the pathologist were according to Desmet & 
Scheuer (Fibrosis stage 0-4) with stage 0: no fibrosis, stage 1: minimal fibrosis, mild 
portal connective tissue, stage 2: mild fibrosis increased portal fibrosis with beginning 
extension into/affection of the hepatic lobule, stage 3: moderate portal connective 
tissue formation with incomplete and complete septa, and stage 4: hard for grading, 
numerous septa complete with the transition to cirrhosis. 
2.2.6. Biochemical studies 
2.2.6.1. Determination of TG content in the liver tissue 
Frozen liver samples (ca. 100 mg) were homogenized in ice-cold 2 x PBS by using a 
Tissuelyser. Tissue lipids in each sample were extracted with 2:1 methanol/ 
chloroform, vacuum dried, and re-suspended in 50 µL (3:2) tert-butanol + TRITON 
MIX (Triton x-114/ methanol (2:1)). TGs levels were colorimetrically determined using 
a commercially available kit. Values were normalized to the initial wet weight of liver 
portion and expressed as g TG/g liver. 
2.2.6.2. Biochemical parameters 
After an overnight (10 h) fasting, the collected rat heparinized blood was centrifuged 
at 3,500 xg for 15 min at 4°C. The harvested plasma samples were studied for 
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glucose, uric acid, urea, total cholesterol, TG, high-density lipoprotein containing 
cholesterol (HDL-C), and low-density lipoprotein containing cholesterol (LDL-C) 
concentrations by using the appropriate kits. The activities of liver transaminases 
(ALT and AST) were also determined in the sera by utilizing the automated systems 
of the central laboratory of the Department of Clinical Chemistry in University Medical 
Center Goettingen. 
2.2.6.3. Leptin assay 
Radioimmunoassay (RIA) is a sensitive technique that quantifies the concentration of 
certain antigens (proteins) in blood samples. Frozen (-80°C) serum specimens were 
thawed at RT, and the RIA kit was used for measuring leptin levels according to the 
manufacturer’s protocol. 
In brief, 300 µL assay buffer was pipetted to a non-specific binding tube, 200 µL to the 
reference tube, and 100 µL to the rest of tubes. Next, 100 µL of the standard and the 
quality controls were added in duplicate. A 100 µL of serum sample was pipetted in 
duplicate, followed by another 100 µL of 125I-Rat Leptin Tracer (HPLC purified) to all 
tubes. Afterwards, 100 µL of rat leptin antibody was transferred to all tubes expect 
total count tubes and non-specific binding tubes. After vortexing, samples were 
incubated overnight at 4°C. A 1 mL of cold precipitating reagent was added to all 
tubes except to the total count tubes. The tubes were vortexed and incubated for 20 
min at 4°C, followed by another 20 min centrifugation at 2,500 xg. Note: conversion of 
rpm into xg: [xg= (1.12 x 10-5) (r) (rpm)2], r= radial distance in cm, rpm: rotational 
velocity of the rotor. Immediately, the supernatant was decanted of all tubes except 
total count tubes, and the tubes were inverted to remove the excess liquid. To 
calculate the concentration of leptin in the unknown samples, all tubes were counted 
in a gamma counter for 1 min. Standard Curve Range: 0.5–50 ng/mL. 
2.2.7. qRT-PCR analysis 
2.2.8.1. RNA isolation 
Liver tissues RNA were isolated by Qiagen RNeasy Mini Kit. Extracted RNA 
concentrations were spectrophotometrically measured at λ= 260 nm, and RNA’s purity 
was controlled by the ratio of optical density (OD) OD260/OD280 nm and its integrity 
by using 1.2% agarose gel electrophoresis. 
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2.2.7.2. Reverse transcription 
Procedure for SYBRgreen reagent: 
Briefly, DNase-treated total cellular RNA (1 µg) was denatured at 65°C for 10 min in a 
total volume of 10 µL with RNase inhibitor. Thereafter, a master mix consisting of 100 
nmol/L of dNTPs, 50 pmol/L of primer oligo(dT)15, 200 units of moloney murine 
leukemia virus reverse transcriptase (M-MLV RT), 1X RT buffer, and 2.5 mL of 0.1 
mol/L dithiothreitol was added to the denatured RNA samples and incubated for 
reverse transcription at 40°C for 1 h, and 72°C for 10 min to terminate the reaction. 
Complementary DNA (cDNA) was ready to use after addition of 120 µL de-ionized 
H2O. 
Procedure for TaqMan reagent: 
For this purpose, the protocol contains 150 pmol random primers (pd(N)6) instead of 
oligo (dT)15 primers. RT master mix was prepared of 2.5 µL 40 mM dNTP, 5 mL 5x 
RT buffer, 2.5 µL 0.1 M DTT, 1 mL M-MLV RT enzyme, 0.4 µL RNase inhibitor, and 
1.6 µL deionized H2O. The RT reaction was performed by using 1 µg RNA (10 µL), 
and 2 µL random primer pd(N)6 150 pmol, the mixture was heated 10 min at 65°C. 
Then, 13 µL RT-mix was added for each sample and the mixture was incubated for 60 
min at 42°C. A 120 µL deionized H2O was added into the mixture. 
2.2.7.3. Primer design 
Primers for different genes were designed using the program “Primer 3 Input (version 
0.4.0)” (Whitehead Institute for Biomedical Research) and the gene bank data 
(http://www.ncbi.nlm.nih.gov). All the primer sets used for real-time PCR are listed in 
Table 2.1.4. The self-annealing, potential hairpin formation, and self-complementary 
of the forward-reverse primers were examined. Then, the primers sequences were 
blasted to check primer’s pair-specificity and localization within the gene. Primers 
were synthesized by Invitrogen. 
2.2.7.4. Thermal cycler amplification program 
As the name suggests, “real-time” quantitative PCR relies on the monitoring of the 
PCR reaction product as the amplification progresses, with product detection and 
measurement occurring after each cycle. Detection is by means of fluorescence and a 
number of techniques can be used with a variety of machines, the two most common 
methods using either the dye SYBR Green or TaqMan. A 1 µL (6.3 ng) cDNA of each 
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sample was added to 9 µL mixture of targeted primer-pair and Fast Platinum SYBR ® 
Green Universal Master Mix. 
The PCR amplification reactions were carried out in a StepOne system: an initial hold 
step (95°C for 20 sec), and 40 cycles of two-PCR steps (95°C for 3 sec, 60°C for 30 
sec) using specific oligonucleotides (Figure 2.3). All samples were assayed in 
duplicate in 96-well PCR microplates. The PCR amplification program was followed 
by dissociation curve protocol for controlling the specificity of the PCR products. The 
fluorescence intensity of each sample was measured at a particular temperature 
change to monitor amplification of the target gene. The purity of PCR products was 
verified by melting curves and gel electrophoresis. 
Additionally, predesigned TaqMan assays were used for Inos and Tlr4 analysis, and 
the protocols were set according to the manufacturer. Briefly, 5 µL of 2x universal 
PCR MM, 0.5 µL 20x Assay on Demand, 3.5 µL H2O and 1 µL cDNA were mixed and 
run for 10 min at 95°C (initial phase), 95°C for 15 sec and 1 min at 60°C for 45 cycles. 
 
Figure 2.3 qRT-PCR phases. In the initial cycles of PCR, there is no considerable alteration in 
fluorescence signal. This predefined range of PCR cycles is called the baseline. Exponential (doubling) 
amplification occurs because all of the reagents are fresh and available, the kinetics of the reaction 
push the reaction to favoring doubling of amplicon. Linear: as the amplification progresses, some of the 
reagents are being consumed. The speed of reactions slows down, and the PCR product is no longer 
being doubled roundly. Plateau: the reactions have halted. The threshold is set in the exponential 
amplification phase, which is in the logarithmic scale shown linearly. A too low threshold increases the 
noise, while too high threshold amplifies samples, and thus increase the standard deviation. The CT 
value (threshold cycle) is defined as the fractional cycle number at which the fluorescence crosses the 
fixed threshold; it is inversely correlated to the level of gene expression. 
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2.2.8. Western immunoblots 
2.2.8.1. Protein extraction 
Liver samples were protected against proteolytic degradation by placing in ice 
throughout the experiment. About 150 mg of deep-frozen liver slice of each studied 
group was washed with pre-cooled PBS (3x) and placed in a reaction tube containing 
1 mL total lysis cell buffer (Table 2. 6) for homogenization. Processed specimens 
were spun at 12,000 rpm for 10 min at 4°C. The supernatants were retrieved, and the 
pellet was re-suspended again with 1 mL lysis buffer, incubated on ice for 30-60 min, 
and then sonicated for three strokes by 70% (v/v) by an alcohol- and water-cleaned 
sonicator for an entire cell disruption. Chilled-centrifugation was performed again.  
2.2.8.2. Determination of protein concentration 
Whole protein concentration of the collected supernatants was measured by Bradford 
assay using a Bio-Rad protein assay kit with bovine serum albumin (BSA) as a 
standard (2 mg/ mL) and an internal control (1:20, 1:40). 
2.2.8.3. Principle 
The Bradford method (Bradford 1976) is a colorimetric protein assay, which is based 
on the absorbance shift of the Coomassie Blue G dye as a result of protein binding. 
The latter causes color changes from red to blue (maximal absorbance at 595 nm) by 
protons donation process. The Bradford assay is linear in a range between 2 - 120 
μg/mL. Herein, the absorbance at 595 nm is directly proportional to the amount of 
protein in the sample. A regression curve was derived from a series of standards 
between 0.03 μg and 1 mg BSA and used to construct an equation for the estimation 
of the unknown protein concentrations. 
Coomassie blue stain was diluted 1:5 with ddH2O, and filtrated. The protein extracts as 
well as the internal control (2 mg/ mL BSA) were diluted with ddH2O to 1:20 and 1:40, 
5 µL of protein dilution, standard, and control were loaded in duplicate on a 
microplate, followed by the addition of filtered Coomassie dye solution, and after 5-10 
min incubation at RT the plate was read at 595 nm. Finally, the concentrations were 
calculated by using the regression curve. 
 
 
2. Materials and Methods                                                                                         50 
   
 
 
Table 2.6 Lysis buffer used for protein extraction in Western blots. 
Reagent  Final concentration 
Tris-HCl (pH= 7.00) 20 mM 
NaCl 150 mM 
MgO2 1 mM 




The pre-stained molecular weight marker or the pre-stained PageRulerTM from 
Fermentas were loaded in a separate lane. The electrophoresis was done at a 
constant current of 50 mA with maximum voltage set at 100 V for 2 h. 
2.2.8.4. Western blots procedure 
Western blot method was used to further analyze the protein samples after separation 
by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). The 
separated proteins were transferred from the gel to a nitrocellulose membrane and 
analyzed by specific primary antibodies. The primary antibodies are then detected by 
horseradish peroxidase conjugated secondary antibodies that are directed against the 
Fc region of the primary antibody. The conjugated peroxidase catalyzes the oxidation 
of luminol resulting in a chemiluminescence emitting reaction that can be used for the 
specific detection of the target proteins. 
As much as 50 μg of whole lysate from each liver sample was separated by (4-12%) 
SDS-PAGE. Proteins were then electroblotted onto Hybond-ECL nitrocellulose 
membranes, and equal loading was monitored in Ponceau S stain. Subsequently, 
non-specific binding sites on the membranes were blocked at RT for 1.5 h in 5% (w/v) 
skim milk and 0.1% (v/v) Tween-20 in PBS and incubated with the first antibody 
overnight on agitated plates at 4°C. Consecutively, the membranes were washed 3 
times for 5 min with PBS-T and incubated with appropriate horseradish peroxidase-
conjugated secondary antibodies. Immunodetection was performed according to the 
ECL chemiluminescent solutions A and B Western blotting protocol. Antibodies that 
were used to study LCN2, inflammation-related proteins and oxidative stress markers 
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are listed in Table 2.1.3. Immunoreaction signals were viewed with enhanced 
chemiluminescence using a film processor machine. All Western blot experiments 
were performed in triplicate. The uniformity of protein loading in each lane was 
assessed by determining the signal of β-actin as a control-loading protein. 
2.2.9. Double immunofluorescent analysis for LCN2 and MPO or ED1 
Immunofluorescence was used to detect the localization of the target antigens within 
liver tissues. Liver cryostatic sections (5 µm) were air-dried and fixed in methanol/ 
acetone for 9:1 min at -20°C on superfrost slides. After blocking of non-specific 
binding with serum (according to the species of the secondary antibody) for 1h at RT, 
the sections were incubated with a solution of the primary antibody anti-LCN2 
combined either with ED1 (CD68, a marker for macrophage) or myeloperoxidase 
(MPO, marker for PMN) overnight at 4°C. In parallel, negative control 
immunostainings were performed by replacing the primary antibodies with PBS or 
isotype matching control IgGs (Wojcik et al. 2012). Alexa flour-conjugated secondary 
antibodies were used to detect the primary antibodies (Table 2.1.3). Cells nuclei of the 
stained sections were remarked by DAPI and the slides were covered with 
Fluoromount-G and observed using an epifluorescence microscope. 
2.2.10. Enzyme-linked immunoadsorbent assay (ELISA) for serum LCN2 
2.2.10.1. Principle 
This assay employs the quantitative sandwich enzyme immunoassay technique. A 
microplate is pre-coated with a monoclonal antibody specific for rat LCN2 protein. 
Serum samples are pipetted into the wells and the immobilized antibody binds LCN2 
protein. After washing away any unbound materials, biotinylated rat NGAL antibody 
specific for rat LCN2 is added. Any unbound antibody-enzyme reagent is washed 
away, and a substrate solution is added to the wells. The enzymatic reaction yields a 
blue-colored product that turns yellow when the stop solution is added. The intensity 
of the color measured by a colorimetric method is directly proportional to the amount 
of protein bound in the initial step. 
2.2.10.2. Reagent preparation 
The reagents box was brought at RT. All reagents/working solutions that are 
necessary for the ELISA were prepared prior to assay procedure as all samples 
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should be pipetted within 15 min. The following instructions were recommended by 
the manufacturer: 
Wash solution: dilute the 25x Wash Solution Conc. by pouring the total contents of the 
bottle (40 mL) into a 1L graduated cylinder and add distilled or de-ionized water to a 
final volume of 1 L. Mix thoroughly and store at 2-8°C till use. Sample diluent: dilute 
the 5x sample diluent conc. by pouring the total contents of the bottle (50 mL) into a 
250 mL graduated cylinder and add distilled or deionized water to a final volume of 
250 mL. Mix thoroughly and store at 2-8°C for use. Ready to use reagents: Rat NGAL 
calibrators (conc. 0 - 400 pg/mL), biotinylated rat NGAL antibody, HRP-streptavidin, 
TMB substrate, and stop solution. Negative controls were prepared by using 100 µL of 
sample diluent per well in duplicate (0 µL serum samples was added). 
2.2.10.3. Assay procedure 
All specimens were assayed in duplicates. This procedure consists of five steps 
excluding the 96-microwells plate washing. In the 1st step, 100 μL volumes of each 
calibrator, diluted non-hemolytic samples, and the internal controls were pipetted into 
their corresponding positions in the microwells. To synchronize the reaction in each 
well, all reagents were pipetted using a multi-channel pipette. Wells were covered and 
incubated for 60 min at RT on a shaking platform set at 200/min. The contents of the 
microwells were pushed out and washed three times with 300 μL diluted wash 
solution. Next, 100 μL of biotinylated rat NGAL antibody was dispended into each 
microwell. The wells were again masked and incubated for 60 min on a shaking 
platform set at 200/min. After washing, 100 μL of HRP-streptavidin was dispended 
into each microwell and incubated for 60 min on a shaking platform set at 200/min. 
Next, the plate was washed three times. Stepwise, 100 μL of TMB substrate was 
pipetted into each microwell. The wells were covered and incubated for exactly 10 min 
at RT in the dark. Finally, to stop the enzymatic reaction, 100 μL stop solution was 
added to each well, maintaining the same pipetting sequence as above and mixed by 
gentle shaking for 20 sec. Optical density of each well was determined within 20 min 
by using a microplate reader at 450 nm. 
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2.2.11. Two-dimensional gel electrophoresis (2-DE) 
2.2.11.1. Protein extraction and determination 
Protein extraction for the 2-DE method was similar to the procedure which is 
mentioned in Section 2.2.8.1. However, the lysis buffer for 2-DE is different (7 M urea, 
2 M thiourea, 4% (w/v) CHAPS, 2% (v/v) ampholytes, 1% (w/v) DTT, 10 mM PMSF, 
and 1% (v/v) phosphatase inhibitor cocktail 2 and 3). The concentration of the isolated 
proteins was measured as described in Section 2.2.8.2 and 2.2.8.3. 
2.2.11.2. First dimensional gel electrophoresis 
The separation of the proteins based on their charge and mass can be achieved by 2-
DE gels according to the protocol of Gorg et al. (Gorg et al. 2000). A150 µg tissue-
extracted total protein plus reswelling buffer (0.2% (v/v) ampholytes, 15 mM DTT and 
370 mM bromophenol blue plus to 0.91 mL lysis buffer) up to 330 µL was centrifuged 
at 4°C, 12,000 rpm for 10 min. The resultant supernatant was used to passively 
rehydrate 17 cm immobilized pH gradient (IPG) strip with a nonlinear pH range of 3-
10 (ReadyStripTM) at RT for 1 h. The IPG strips were then macerated in reswelling 
tray with 2 mL low viscosity mineral oil for each to prevent the evaporation process, 
followed by incubation for 14 h at RT. Subsequently, strips were soaked in 2 mL 
mineral oil and applied in Protean IEF Cell at 20°C and 32,000 Vh. The proteins were 
separated in the first dimension according to their isoelectric points (isoelectric 
focusing (IEF)). 
2.2.11.3. Gel preparation for 2-DE 
The SDS-PAGE was used to separate proteins according to their molecular weight 
(MW) (Laemmli 1970), i.e. the polyacrylamide matrix acts as a molecular sieve. The 
anionic detergent SDS is used to denaturate the proteins by disrupting the non-
covalent bonds so interactions can be prevented, and the use of the reducing agent β-
mercaptoethanol in the sample buffer leads to the dissociation of subunits of the 
multimeric proteins. SDS negatively charges the unfolded proteins, which makes them 
to migrate to the positive electrode (anode) in the electrophoretic gel. Usually, 12% 
acrylamide gels were used and a 4% stacking gel is cast onto the resolving gel, leads 
to a decrease in sample spread (Table 2.12). PROTEAN II xi XL Vertical 
Electrophoresis Cells were used for gel formation. 
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Table 2.12 The composition of the phase 1 and 2 gels. 
Reagents Stacking (4%) 4 gels Resolving (12%) 4 gels 
1.5 M Tris/HCl  1.5 mL, pH 6.8 38.5 mL pH 6.8 
30%Bis/Acrylamid 1.56 mL 64.2 mL 
10% (w/v) SDS  60 µL 2.2 mL 
10% (w/v) Ammonium persulfate  60 µL  770µL 
TEMED  6 µL  51 µL 
ddH2O 8.8 µL 49.3 mL 
 
  
2.2.11.4. Second dimensional gel electrophoresis 
IPG strips were placed in two equilibration buffers contain 6 M urea, 0.15 M Tris/HCl 
pH 8.8, 2% (w/v) SDS, 30% (v/v) glycerin, and 15 mM DTT + 0.25% bromophenol 
blue or 40 g/L Iodoacetamide + 0.25% bromophenol blue for 30 min each. Softened 
IPG strips were lengthwise compressed into a vertical loose 4% gel phase after 
getting rid of excess oil. A 5 µL pre-stained molecular marker-wetted filter paper was 
aligned on the left side of the strip. 1x electrophoresis buffer was diluted from (1 liter 
5x concentration: 0.025 M Tris (pH 8.3), 0.192 M glycine, and 2% (w/v) SDS) was 
used in the second dimensional SDS-PAGE protein separation based on molecular 
weight for 18-20 h at 4°C and 90 V through a 12% stacking gel in Bio-Rad Protean II 
xi Cell. As a result, the similar IP proteins bands were further separated according to 
their molecular weights in individual spots on the gel slabs. 
2.2.11.5. Phospho- and silver-staining of proteins 
After 30 min fixation of the 2-DE gels with 50% (v/v) methanol + 12% (v/v) glacial 
acetic acid), the gels were washed 3x with ddH2O. The gels were then phospho- 
stained in the dark by overnight incubation with Pro-Q® Diamond Phosphoprotein gel 
stain according to the manufacturer’s directions. Next, the gels were de-stained for 30 
min (3x) using 20% (v/v) acetonitrile and 5% (v/v) 50 mM sodium acetate, pH 4. The 
stained gels were finally washed 3x with ddH2O and scanned (Fla 5100) at λ= 532 nm. 
Silver staining is a popular and sensitive protein staining method, with a detection 
range of 1-10 ng (Wise and Lin 1991). For protein silver staining using the modified 
method of Blum et al. (Blum et al. 1987), the gels were washed in graded ethanol for 
30 min. Next, they were sensitized with freshly-prepared 100 mL/gel of 0.8 mM 
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sodium thiosulfate for 1 min followed by rinsing with three changes of ddH2O for a total 
of 1 min. The gel slabs were submerged in freshly prepared 12 mmol sliver nitrate and 
0.026% formaldehyde for 20 min shaking at RT. After three ddH2O washes; the protein 
color was developed using developing buffer (sodium carbonate 6%, formaldehyde 
0.0185% of 37% formaldehyde stock, and sodium thiosulfate 16 µM) with intensive 
shaking. The silver-stained gels were stored in 5% (v/v) glacial acetic acid, scanned 
and finally dried with vacuum gel dryer for 1.5 h at 80° C for further storage and 
analysis. 
2.2.11.6. Analysis of protein spots in the 2-DE polyacrylamide 
The two dimensional gel electrophoresis was developed to analyze the final level of 
gene expression based on resultant proteins (O'farrell et al. 1977). Densitometric 
analysis was accomplished using the Delta2D software V4.2. Gel images of controls 
and the experimental groups were warped and aligned to correct for differences in 
protein separation and migration between gels. Protein spots were detected 
automatically and verified manually using the dual view of the Delta2D software. After 
background subtraction, the measured intensity of each protein spot was normalized 
as a percentage to the total intensity of all integrated protein spots of the scanned 
images of polyacrylamide gel (Luhn et al. 2003). The definition for differential 
expression of proteins was set to at least 1.5-fold increase or decrease in spot 
intensity that was significant compared to control at least at P< 0.05. 
2.2.12. In vitro studies 
2.2.12.1. Primary liver cell isolation and culturing 
2.2.12.1.1. Animal preparation 
Rat hepatocytes (HCs) were isolated from livers of male Sprague-Dawley rats (240 g) 
based on two-step enzymatic (collagenase) perfusion, a method which was firstly 
described by Seglen (Seglen 1973). Animals were anesthetized with Narcoren® 50% 
of BW (240 g), and were rested on their backs using clamps/pins. The abdominal 
region was disinfected with 70% ethanol. Using a large 1.3 mm diameter cannula; the 
portal vein was punctured and connected longitudinally via sterile tubing to the pump 
system. 
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2.2.12.1.2. Liver perfusion 
The liver was initially exsanguinated in non-recirculating mode via the portal vein in 
situ at a rate of 10 mL/min with 200 mL CO2-enriched calcium-deprived sterile Krebs–
Ringer buffer (KRB, Table 2.14) pH 7.4 containing 0.25 mM EGTA until liver becomes 
bloodless. By perfusion with the calcium-free solution, calcium ions were eluted from 
the desmosomes, resulting in a large cell yield with minimum cell damage. For a 
sacrifice of the experimental animal, the diaphragm muscle was opened. 
Components of the extracellular matrix of the rat liver were enzymatically digested by 
a perfusion medium (buffer II) for 7-12 min at 37°C with ~ 150 bar carbogen in a firstly 
non-recirculating mode until the perfusion system filled with buffer II, and then under 
recirculating conditions for 15 min by cannulating the inferior vena cava with soft a 
tube to the pump system. Glisson’s capsule was carefully torn away, and the liver 
tissues were manually disrupted to yield a crude cell suspension. The suspension of 
the cells was filtered by pouring over a beaker covered by a nylon mesh filter (pore 
size 79 μm). HCs and other cells entered through the pores, while undigested 
connective tissues and remainder aggregates were retained (Figure 2.4). 
Nonparenchymal cells and cell debris were removed by thrice centrifugation in total 
(1,200 rpm, 2 min, RT) with cold wash with buffer III (pH 7.4, 120 mM NaCl, 4.83 mM 
KCl, 1.2 mM MgSO4.7H2O, 1.2 mM KH2PO4, 20 mM HEPES, and 0.4% BSA). The 
pellet was re-suspended with Percoll-gradient solution. Subsequently, the cells were 
re-suspended in culture media and were chamber counted (Neubauer 
hemocytometer). The final cell pellet predominantly contains HCs (90%, as originally 
described) (Ates M et al. 2012). HCs were 85-90% viable. This procedure was 
ethically approved (Ramadori et al. 1990). 
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Figure 2.4 The status of rat liver during HC isolation. A-B. Blood was flushed from the liver. C. The 
liver was softened as a result of collagenase treatment. D. The liver was excised and washed in PBS. 
E. The liver was crushed and filtered. 
 
Table 2.14 Buffer I: Pre-perfusion, Ca-free KRB + EGTA pH (7.4) KRB. 
Molar  Mass/ 1L 
24 mM NaHCO3 2.016 g/L 
120 mM NaCl 7.020 g/L 
4.83 mM KCl 360 mg/L 
1.2 mM MgSO4.7H2O 296 mg/L 
1.2 mM KH2PO4 163 mg/L 
Buffer II: Collagenase-containing medium pH (7.4) 
 
2.2.12.1.3. HCs treatment 
Isolated primary HCs (1 million/ mL) were grown in large culture plates (9 cm) in M199 
supplemented with 1.5% (v/v) penicillin-streptomycin, 4% (v/v) FCS and 1 nM swine 
insulin at 37°C in a 5% CO2, 95% air- humidified incubator for 40 h. Afterwards, the 
cells were fasted for 4 h by replacing the culture medium with glucose-free medium 
plus other supplementary constituents. Thereafter, the isolated HCs were treated with 
either 20 mM glucose (glu) or equimolar fructose (fru) in M199 medium. Next, the 
medium was aspirated out and replaced with PBS. Subsequently, the cells were 
harvested and lysed kinetically at 0, 3, 6, 12, and 24 h for RNA and protein studies 
either by Qiagen reagents or Western blot lysis buffer (Section 2.2.9.1). Concurrently, 
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culture medium of each sample was also collected for protein evaluation. All 
treatments were carried out in duplicate. 
2.3. Statistical analysis 
Data were processed using the GraphPad Prism 5 software and were described as 
mean ± standard error of the mean (SEM). Statistical significance was calculated by 
one-way analysis of variance (ANOVA) (Dunnett’s post-hoc test) to examine the 
statistical significance in experimental groups versus controls. For statistical analysis 
of RT-PCR results, the comparative CT– method was used to determine the amount of 
target gene transcripts, normalized to an endogenous reference (housekeeping gene 
transcript, β-actin and ubiquitin c) and relative to a calibrator (arithmetic formula; 2-
∆∆Ct). For 2-DE data, ANOVA cluster analysis and T test were used. The null 
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Part I: Animal Model 
3.1. Animal phenotypes and biophysical parameters 
3.1.1. L-HFr fed rats exhibited increases of food intake 
The rats were treated with standard chow (Co), liquid Lieber De-Carli (LDC) or LDC 
plus 70% fructose (L-HFr) diet for 4 wks or 8 wks. Average basal food intake (at wk 0) 
was 25.2 ± 0.5 kcal/100g BW/day for all animals. The food intake of the control rats 
slightly declined at wk 4 (23.5 ± 0.1) and wk 8 (21.2 ± 0.1). There was no noticeable 
difference in the food intake between the Co and the LDC group. Instead, a significant 
increase of food intake was observed in the L-HFr group at wk 4 (33.5 ± 0.7 kcal/100g 
BW/day) and wk 8 (29.0 ± 0.2 kcal/100g BW/day) (Figure 3.1A). 
3.1.2. Variations in the body and liver weights 
The phenotypes of the animals were studied to observe the effect of the diets on the 
BW gain and liver weight (LW). The BW of the Co group was 160-180 g at wk 0 and 
increased up to 393 ± 5 g at wk 4 and 489 ± 7 g at wk 8. The rats of the Co and the 
LDC group had a comparable BW and gained more BW than the animals in the L-HFr 
group during the study. 
Despite markedly higher total caloric intake in the high fructose-challenged rats, the 
absolute BW was significantly diminished at wk 4 (300 ± 7 g; P<0.001) and at wk 8 
(420 ± 16 g; P<0.001). This implies that the BW of L-HFr treated rats was reduced by 
30% and 15% relative to the corresponding age-matched control rats (Figure 3.1B). 
However, these animals remained behaviorally normal and showed no signs of stress. 
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Figure 3.1 Phenotypes of the animals. Linear graphs show the average of caloric daily intake of the 
animals (A) at wk 0, 4 and 8 of treatment (food intake expressed as kcal• g BW-1• d-1) and animal body 
weight (B). Bar blots show liver weight (C) and relative liver weight (D). Data are presented as mean ± 
SEM of four rats per group in correspondence to time points (wks). ** Indicates statistically significant 
difference P<0.01, *** P<0.001. Standard chow pellet (Co), a freshly prepared liquid LDC: Lieber DeCarli 
(LDC), and LDC combined with 70% fructose (L-HFr). 
 
In general, the LW of both animal groups was moderately higher than that of littermate 
controls (Figure 3.1C). LW of the Co group was 12.3 ± 3 g at wk 4 and 14.5 ± 0.3 g at 
wk 8, while in the LDC group it was 13.1 ± 0.7 at wk 4 and 15.7 ± 0.5 g at wk 8. In 
addition, the LW under the L-HFr regimen was 12.6 ± 0.4 g and 16.4 ± 1.0 g at wk 4 
and 8, respectively.  
Consequently, RLW (LW• g BW-1• 100%) was high in both experimental groups 
compared to controls. The LDC-fed animals had slightly higher RLW (3.5 ± 0.2%, and 
3.3 ± 0.1%) compared with that of the fed animals standard Co (3.1 ± 0.1%, 3.0 ± 
0.1%) at wk 4 and 8, respectively. Yet, the RLW of L-HFr fed rats was the highest (4.5 
± 0.1% at wk 4 and 4.0 ± 0.4% at wk 8) during the observation period (P<0.001) (Figure 
3.1D). 
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3.2. Fatty liver developed in the LDC and the L-HFr group 
As the contents of the livers in the groups are different, the LW is imprecise. Thus, size 
(scale) of the liver and its general appearance were additionally evaluated. The Co-fed 
animals exhibited normal liver size and morphology at both time points. In the LDC 
reared rats, liver size was insignificantly larger, while the liver was somewhat lighter 
than the liver colors observed in the Co group (scale, Figure 3.2). Of note, the L-HFr 
fed rats presented hepatomegaly as well as yellowish, greasy and soft livers compared 
to other groups at both time points (Figure 3.2). In the L-HFr fed rats, visceral fat 
deposition in the abdominal cavity was noticeably higher 
 
 
Figure 3.2 An overview of the rat liver and visceral adipose tissue after laparotomy. Co: grossly, 
liver color is brown, and the surface is smooth, microscopic: normal liver, no fat droplets; LDC: grossly, 
liver color is light brown; L-HFr: liver is enlarged and greasy, and it has a pale yellow appearance. In 
addition, more visceral fat (perirenal black arrow and mesenteric white arrow areas) can be seen in L-
HFr fed animals. Since there was no difference in the general appearance of the livers of the same group 
at both time points, only wk 4 is presented above. 
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Furthermore, the histological manifestations of the liver tissue were microscopically 
assessed by Oil Red O, Nile red, HE, and Masson’s Trichrome staining. 
3.2.1. Hepatic lipid partitioning in the animal groups 
Lipid distribution in the liver varied among the animal groups. Oil Red O, a specific lipid 
staining, revealed no lipid accumulation in control livers (Figure 3.3). In LDC fed rats, 
fat microvesicles were observed primarily in the HCs of the portal triad at wk 4. Micro 
vesicular and occasionally macrovesicular steatosis were evidenced in the LDC group 
at wk 8 (Figure 3.4). The uniform liver change in the L-HFr group was consistent with 




Figure 3.3 Representative micrographs illustrate lipid deposition. Cryo-liver sections were stained 
with Oil-Red O at wk 4. The red color represents the accumulated lipid droplets in the HCs, while the 
blue color represents the hematoxylin-stained nuclei. A massive lipid accumulation is visualized in the 
portal area towards the central vein in the L-HFr group. PV: portal vein, HCs: hepatocytes. Magnification 
x100.  
 
The liver sections were stained with TG-specific Nile red dye for further confirmation. 
The LDC as well as the L-HFr diet induced hepatosteatosis with different degrees 
compared to the control group. Different sizes of fat droplets can be seen in the livers 
of the L-HFr fed group (Figure 3.4).  
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Figure 3.4 Photomicrographs of Nile red stained liver sections. The staining demonstrates the 
TG retention in the HCs of the LDC and the L-HFr group. Intracellular accumulated fat was 
exhibited in green or red small vesicles (LDC group) and almost large vesicles (L-HFr group). 
Since there is no difference in the morphology of Nile red staining between the time points, the 
presented pictures were collected at wk 8. The rats were fed with standard chow (Co), liquid 
Lieber-DeCarli diet (LDC) or LDC + 70% kcal fructose (L-HFr). The magnification of left and 
middle columns is x100, whereas in the right one it is x200. The nuclei were stained with DAPI 
and they appear Blue. 
 
3.1.2. HE staining manifested macrosteatosis, HCs ballooning, and moderate 
inflammation in the L-HFr group 
Histopathological examination of the liver tissue in each animal group was mostly 
consistent. Control (chow-fed) rats showed normal hepatic architecture and there was 
no sign of steatosis, inflammation or fibrosis. The livers of rats fed with liquid LDC diet 
showed admixture of micro- and/or macrovesicular steatosis commonly observed in 
periportal areas at wk 4 (Figure 3.5A) and wk 8 (Figure 3.5B), respectively. Instead, 
livers of L-HFr treated rats were distinguishable from those of rats fed with chow or 
LDC diet. Hallmarks of NASH included extremely panacinar/ panlobular steatosis 
(covering the total surface of the hepatic lobule) and moderate inflammation (grade 2) 
noticed mainly in zone I of the L-HFr group at both time points. 
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Figure 3.5A HE-stained livers at wk 4. The rats were fed with standard chow (Co), liquid Lieber-DeCarli 
diet (LDC) or LDC + 70% kcal fructose (L-HFr). The left column represents x100 overview and the right 
column represents x400 magnification. Microvesicular steatosis is present in the periportal area (zone I) 
of the livers of the LDC group. Pronounced macrovesicular steatosis in zone I and II is observed in the L-
HFr group. The right column focuses on the perivenular area which shows mostly intact HCs in Co and 
LDC. In contrast, HCs ballooning surrounds the CV area. Red arrows point to ballooned HCs, the black 
arrow shows foamy HCs. CV: central vein, PV: portal vein. The white clear vacuoles contained lipid. 
However, since histological fixation caused it to be dissolved only empty/clear spaces can be seen. 
 
Pronounced macrovesicular fat degeneration indicating that the cytoplasm of the 
hepatocyte is occupied by a single large fat droplet that displaces the nucleus to the 
periphery (eccentric nucleus) was the major feature under the L-HFr regimen. At wk 8, 
however, the percentage of fat-laden HCs was lesser than at wk 4 in the L-HFr group. 
Moreover, ballooned HCs were seen in centrilobular areas, along with a loss of 
structural integrity and vascular architecture at both time points. The perivenular HCs 
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revealed a foamy fatty change characterized by striking cell swelling with additional 
massive infiltration of small fat droplets throughout the cytoplasm. The nuclei in these 
cells are almost centrally located. 
 
 
Figure 3.5B Photomicrographs of HE staining of wk 8 hepatic tissue. Normal liver features are 
presented in the Co group, admixture of macro and micro steatosis can be evidenced in the LDC group. 
Pronounced panacinar/panlobular steatosis seen in the L-HFr group with moderate inflammation. Rats 
were reared on Co: chow (control), LDC: Lieber-DeCarli, or L-HFr: LDC + high fructose (70%) diet. Left 
column x100, right column x200 magnification. 
 
Percentage of fat-loaded HCs was histologically evaluated by a pathologist and three 
different scientists (Figure 3.5C).  
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Figure 3.5C Percentage of fat-laden HCs. The evaluation was microscopically performed on the HE-
stained liver slices * P<0.05, *** P<0.001 vs. Co. Data were presented as mean ± SEM of four rats per 
group. Rats were fed for 4 wks or 8 wks with standard chow (Co), liquid Lieber-DeCarli diet (LDC) or 
LDC + 70% kcal fructose (L-HFr). HCs: hepatocytes. 
 
3.2.3. Stages of liver fibrosis in the experimental groups 
No fibrosis was seen in the control and the LDC group at wk 4. In addition, at wk 8 the 
control group showed the same liver features seen at wk 4, while the LDC group 
exhibited stage 1 fibrosis (minimal fibrosis, mild portal connective tissue) at wk 8. The 
L-HFr regimen resulted in progressively fibrosing livers: stage 1 fibrosis at wk 4, and 
stage 2 (mild fibrosis, increased portal fibrosis with beginning extension into/affection of 
the hepatic lobule) at wk 8 (Figure 3.6). In addition, the liver architecture was somewhat 
impaired in the L-HFr animal model. The slides were classified according to Desmet & 
Scheuer (stages of fibrosis 0-4, grade of inflammation 0-4) by a pathologist. 
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Figure 3.6 Masson’s Trichrome stained liver slices. At wk 4 (left column), both the Co and the LDC 
group showed no fibrosis (stage 0), while the L-HFr group showed stage 1 (minimal, mild portal 
connective tissue). At wk 8 (right column), the hepatic features were the same as at wk 4 in the Co 
group, the LDC group showed stage 1 fibrosis, whereas the L-HFr animal model had stage 2 (mild 
fibrosis, increased portal fibrosis with beginning extension into/affection of the hepatic lobule). The rats 
were fed with standard chow (Co), liquid Lieber-DeCarli diet (LDC) or LDC + high (70% kcal) fructose (L-
HFr) regimen. Magnification (x100). 
 
3. 3. Biochemical Studies 
3.3.1. Hepatic TG content 
Intrahepatic TG loading was further measured. In the control liver tissues, 1.4 ± 0.1 g 
TG was assessed in 1 g at wk 4. This value was slightly higher (1.8 ± 0.1 g TG/g liver) 
at wk 8 in the same group. In agreement with the histological assessment, the LDC diet 
induced an approximately 1.8-fold increase in hepatic TG content respective to chow 
3. Results                                                                                                                    68 
   
 
 
diet. Moreover, a three-fold increase of TG content was found in the livers of the L-HFr 
fed rats at wk 4 and a two-fold increase at wk 8 (Figure 3.7). 
 
 
Figure 3.7 Triglyceride content in the rat liver. Data are expressed as mean ± SEM of four 
animals/group per time point. The rats were fed with standard chow (Co), Lieber-DeCarli (LDC), or LDC 
plus high fructose (L-HFr) diet. The food was removed 10 h before the sacrifice. * P<0.05, ** P<0.01, *** 
P<0.001 vs. Co. 
 
3.3.2. Plasma biochemical profiles differed markedly in the L-HFr model 
The LDC diet resulted in significantly increased fasting TG concentration in the plasma 
compared with littermate controls at wk 4, but not at wk 8. Although the levels of fasting 
glucose, total cholesterol and ALT and AST were numerically higher in the LDC group 
than in the control group, the difference was not statistically significant (Table 3.1). The 
L-HFr diet resulted in increased levels of blood TG and glucose compared to controls 
(Table 3.1). Consistently, the concentration of total plasma cholesterol was moderately 
higher in the L-HFr animal model compared to the age-matched control group. 
Moreover, the plasma level of HDL-C (the “good” cholesterol) was diminished in the L-
HFr rat group after 8 wks (P<0.001) (Table 3.1). The LDL cholesterol levels remained 
unchanged in all groups (data not shown). In addition, the L-HFr diet was associated 
with a two-fold increase in plasma uric acid concentration at wk 8 (P<0.01). Serum ALT 
and AST activities were significantly increased in the L-HFr model (P<0.05) at both 
studied time points (Table 3.1). 
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Co LDC L-HFr 
ALT (U/l) 
4 wks 41 ± 8 43 ± 3 69 ± 7 * 
8 wks 55 ± 8 48 ± 4 80 ± 8 * 
AST (U/l) 
4 wks 67 ± 5 74 ± 2 136 ± 8 ** 
8 wks 90 ± 7 117 ± 13 166 ± 10 ** 
Glucose (mg/dl) 
4 wks 152 ± 12 182 ± 5 243 ± 4** 
8 wks 210 ± 7 244 ± 5 292 ± 6 *** 
TG (mg/dl) 
4 wks 26 ± 5 74 ± 8* 75 ± 13 * 
8 wks 44 ± 13 62 ± 15 127 ± 21 * 
Cholesterol (mg/dl) 
4 wks 55 ± 2 58 ± 4 58 ± 3 
8 wks 47 ± 4 52 ± 4 53 ± 5 
HDL-C (mg/dl) 
4 wks 49 ± 1 43 ± 2 46 ± 1 
8 wks 44 ± 1 45 ± 3 32 ± 2 *** 
Uric acid (mg/dl) 
4 wks 0.6 ± 0.0 0.9 ± 0.2 0.5 ± 0.0 
8 wks 1.1 ± 0.0 0.5 ± 0.1 2.2 ± 0.3 ** 
All animals were overnight fasted before sacrifice. The hallmarks of metabolic syndrome were induced in 
the L-HFr group. The animals were fed with: Co: chow (control), LDC: Lieber-DeCarli liquid diet, or L-
HFr: LDC + 70% kcal fructose. * P<0.05, ** P<0.01, *** P<0.001 compared with control group: Data are 
expressed as mean ± SEM of four rats per group. 
 
3.3.3. Changes in serum leptin levels 
Leptin is a 16-kDa protein hormone made by fat tissue that plays a key role in 
regulating energy intake, satiety and expenditure, including appetite and hunger, BW 
changes (Friedman and Halaas 1998). It is encoded by the ob gene. Sugar 
consumption elevates fasting leptin concentrations and the increases are associated 
with BW changes (Rezvani et al. 2013). The leptin also augments the release of 
proinflammatory cytokines (TNF-α and MCP-1) in mice (Chatterjee et al. 2013). The 
diurnal pattern of leptin is disrupted by fasting, and its concentration decreases 
dramatically in response to overnight fasting (Weigle et al. 1997).  
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Fasting leptin levels were measured in serum samples using RIA. Obviously, leptin 
concentrations at wk 8 were higher compared to wk 4 in all groups (Figure 3.8). At wk 
4, the leptin level in the control group was 1.8 ng/mL and in the LDC group, 3.0 ± 0.2 
ng/mL. Interestingly, the fructose-enriched diet elevated leptin levels up to 5.1 ng/mL 
(2.8-fold) compared to age-matched controls (P<0.01). At wk 8, the leptin serum level 
in the Co group was 3.7 ± 0.9, and in the LDC group 5.7 ± 2.1 ng/mL. Although in the 
normal situation of the blood leptin should decrease during fasting, the L-HFr regimen 
caused a 3.3-time increase of fasting leptin level compared to control rats (P<0.01) 
(Figure 3.8).   
 
 
Figure 3.8 Fasting serum leptin levels.  The values (ng/mL) were expressed as mean SEM of four rats 
per group. The rats were fed with Co: control, LDC: Lieber DeCarli diet or L-HFr: LDC + high (70% kcal) 
fructose for 4 or 8 wks. ** P<0.01 vs. Co.   
 
Part II: Lipocalin-2  
3.4. Changes of hepatic inflammation- and metabolism-related genes 
3.4.1. mRNA transcript of Lcn2 increased significantly in the L-HFr group 
To explore whether both animal models of nonalcoholic induced fatty liver (LDC and L-
HFr) will noticeably express Lcn2 in the liver tissue, qRT-PCR was used. Interestingly, 
the mRNA specific transcript of Lcn2 was not significantly changed in the livers of LDC-
fed rats at wk 4 and wk 8 compared to corresponding control rats. Alternatively, a 
significant increase of hepatic Lcn2 expression was detectable in the L-HFr category at 
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wk 4 (90 ± 11 fold; P<0.001) and at wk 8 (507 ± 28 fold; P<0.001) (Figure 3.9). The 




Figure 3.9 Bar plot shows relative expression of Lcn2 in the liver. Each bar represents the mean ± 




 wk. * Indicates statistically significant difference (*** P<0.001). 
The animals were nourished with standard chow pellet (Co), a freshly prepared liquid Lieber DeCarli 
(LDC) or LDC combined with 70% fructose (L-HFr).  
 
3.4.2. Expression of inflammation-related genes in the liver samples 
The following inflammation-related genes were measured in this study at wk 4 and 8: 
interleukin-8 (Il-8), a potent activator of polymorphonuclear neutrophils (PMN); Mcp-1 
which recruits monocytes and granulocytes; α2-m, a positive acute phase protein in 
human and rat; Tnf-α, a pro-inflammatory cytokine; Inos, involved in innate immunity 
and oxidative conditions; and Tlr4, a pathogen recognition receptor. The regulation of 
these genes did not significantly differ between the LDC and the Co group at both time 
points. Conversely, in the L-HFr group, the mRNA expressions of Il-8 (30-fold), Mcp-1 
(4.9-fold), α2-m (9.4-fold), Tnf-α (4.5-fold), Inos (5.6-fold) and Tlr4 (7.1-fold) were 
significantly augmented at wk 4 (Figure 3.10 A-F). Noticeably, upregulations were also 
found of Il-8 (13-fold), Mcp-1 (3.6-fold) and α2-m (5.7-fold) in the L-HFr group at wk 8 
(Figure 3.10A-C). At this time point, however, no significant changes in Tnf-α, Inos and 
Tlr4 expression were found in the same group (Figure 3.10D-F). 
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Figure 3.10 Changes of specific mRNA transcription in the liver. Each bar represents as mean ± 
SEM of four rats/group at wk 4 and wk 8. Data were normalized by ubiquitin C (Ubc). β-actin (Actb) was 
additionally used as a reference housekeeping gene. Standard chow pellets (Co), a freshly prepared 
liquid LDC: Lieber DeCarli (LDC), and LDC combined with 70% fructose (L-HFr). * Indicates statistically 
significant difference (*** P<0.001). 
 
3.4.3. Hepatic Glut5 and Lep-r transcripts were elevated in the L-HFr regimen 
Under the LDC regimen, both levels of Glut5 (the major fructose transporter) and Lep-r 
(leptin receptor) mRNA expression remained almost at the level of the controls. In 
contrast, Glut5 mRNA was considerably enhanced at wk 4 (seven-fold) and wk 8 (six-
fold) in the L-HFr-challenged rats compared to controls (Figure 3.11G). Concomitantly, 
hepatic Lep-r specific transcripts were substantially raised 9.2-fold (wk 4) and six-fold 
(wk 8) in L-HFr fed animals (Figure 3.11H). 
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Figure 3.11 Modulations of Glut5 and Lep-r mRNA in the liver. The rats were fed chow pellets (Co), a 
freshly prepared liquid LDC: Lieber DeCarli (LDC) or LDC combined with 70% fructose (L-HFr). * 
Indicates statistically significant difference (*** P<0.001). 
 
3.5. Changes of the hepatic LCN2 expression at protein levels 
L-HFr treated animals showed an increase of LCN2 expression in the liver. Western 
blots were used to detect the amount of hepatic LCN2 protein. The expression of LCN2 
protein was almost similar in the LDC and the control group. Along with an increased 
Lcn2 mRNA expression in the L-HFr group, the expression of LCN2 protein in the total 
liver homogenates was clearly upregulated (Figure 3.12). Prominently, the maximal 
increase of hepatic LCN2 protein was at wk 8. 
 
 
Figure 3.12 Changes in LCN2 protein expression in the rat liver. Representative immunoblots for 
LCN2 proteins. The animals were fed with standard chow (Co), Lieber-DeCarli (LDC), or LDC plus 70% 
fructose (L-HFr). 
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3.6. Immunohistochemical detection of LCN2, MPO and ED1 in rat liver 
Immunofluorescence staining proved the tissue specific LCN2 localization. The 
positivity of LCN2 in the liver was restricted to MPO+ cells (Figure 3.13, left-panel). Only 
a few LCN2+ cells were observed in the normal (healthy) liver tissues. The LDC fed 
animals presented a similar view as seen in controls, but some LCN2 signals were 
observed in MPO+ cells in the periportal area mainly at wk 8 of the study. Interestingly, 
the highest LCN2 positivity was detected in the MPO+ PMN in the livers of the L-HFr 
group. A possible overlapping between anti-MPO and anti-ED1 was examined by 
double-immunostaining. The positivity of each marker was entirely separated (data not 
shown), indicating that MPO is a PMN-restricted marker. 
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Figure 3.13 Immunolocalization of hepatic LCN2. The LCN2 was double-stained with MPO (a marker 
for PMN, left-panel) and ED1 (a marker for macrophages, right-panel) at wk 4. A co-localization of LCN2 
and MPO can be detected in the liver sections. The blue color indicates the nuclei stained with DAPI. 
The black cavities (vesicles) that were marked by star (*) in the L-HFr micrographs resulted from 
washing, off of the fat from the HCs during the fixation step. The red arrows in the right panel show ED1
+
 
cells, while the white arrow shows the LCN2
+
 cells. Scale bar = 200 μm. MPO: myeloperoxidase, PMN: 
polymorphonuclear neutrophils, ED1: ectodysplasin (CD68), Co: chow diet, LDC: Lieber-DeCarli liquid 
diet, and L-HFr: LDC + 70% fructose. 
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3.7. Serum levels of LCN2 
Serum LCN2 was detected by ELISA. At wk 8, the concentration of serum LCN2 
tended to be higher than the concentration at wk 4 in all groups (Figure 3.14A). The 
LDC group showed a mild increase in serum LCN2 when compared to controls. 
Conversely, the concentration of LCN2 in bloodstream revealed by ELISA was clearly 
augmented in the fructose fed animals (Figure 3.12A). At wk 4, the L-HFr fed rats 
evidenced a two-fold (P<0.05) enhancement in the level of serum LCN2, and a more 
than 2.2-fold (P<0.05) increase at wk 8 in the LCN2 magnitudes. The increase of 





Figure 3.14 Upregulation of systemic LCN2 levels was seen in the L-HFr group. Serum LCN2 data 
(A), values on y-axis were expressed in ng/mL. (B) Representative autoradiographies from Western blots 
determination and the corresponding Ponceau stained membranes of two animals per group are shown. 
Co: Chow diet, LDC: Lieber DeCarli, and L-HFr: LDC + 70% fructose. * P<0.05 vs. Co. 
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3.8. Modulations of hepatic expression of inflammation-related proteins 
Concurrently, the fructose-enriched diets evidently stimulated the protein expression of 
CD14, a multifunctional protein involved in TLR4 signal transduction and apoptosis, 
and MAPK (ERK), is activated by phosphorylation in response to stress and 
coordinates pro-apoptotic functions. Markedly, hepatic IκBα1 protein expression was 
considerably attenuated in the L-HFr group at wk 8 (Figure 3.15). 
 
 
Figure 3.15 Changes in the expression of liver inflammation-related proteins. Representative 
immunoblots for inflammation-related proteins in the liver. Co: Chow diet, LDC: liquid Lieber-DeCarli diet, 
and L-HFr: LDC + 70% fructose. 
 
3.9. Metabolism and oxidative stress related indicators 
To study whether chronic dietary fructose impairs mitochondrial and/or endoplasmic 
reticulum functions, Western blots were performed on hepatic casp 9, the initial casp in 
the mitochondrial apoptotic cascade in response of ROS, and GRP78 a molecular 
chaperone correlates with endoplasmic reticulum stress. It regulates the unfolded 
protein response and 4-HNE, a specific end product of lipid peroxidation.  
In contrast to the Co and the LDC diet, the L-HFr diet induced casp 9, GRP78, and 4-
HNE at both time points (Figure 3.16). However, Cyt c protein, required for 
mitochondrial function and apoptosis, was maximally increased at wk 8. Additionally, it 
has been known that PGC-1α plays a crucial role in the mitochondrial biogenesis (Zhou 
et al. 2012). In the present study, the data showed that the L-HFr diet clearly 
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diminished the hepatic PGC-1α protein expression at wk 8 (Figure 3.16). This result 
was inversely correlated to the patterns of liver LCN2 protein. 
 
 
Figure 3.16 Changes in oxidative stress related proteins in the liver. Co: Chow diet, LDC: Lieber 
DeCarli, and L-HFr: LDC + 70% fructose. Representative immunoblots were shown per group. 
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3.10. 2-DE data analysis 
To screen other possible biomarkers, four animals per group were used for hepatic 2-
DE analysis. Phopho- and silver-staining were performed (Figure 3.17). However, no 
significant regulated protein spot was found in the region between 20 and 37 kDa.  
 
 
Figure 3.17 Representation of two gel images warped by the software Delta2D. The digitized 
images of the master gel (Blue) and the L-HFr group (orange) after a silver-nitrate staining of total liver 
homogenate were placed one above the other by Delta2D. Green color shows the overlapping spots. 
 
3.10.1. Proteins with significantly altered amount 
For investigation of proteins modulated by treatment of rats with L-HFr diet, tissue 
extracts were prepared from treated and untreated rats and separated by 2-DE. One 
phosphoprotein (spot label 2) was significantly higher phosphorylated on treatment of 
rats with HFr-diet. 
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On comparative computational analysis of images of silver-stained 2-DE gels, five 
spots revealed changes in relative intensity. Significant differences (P< 0.05) in protein 
intensity were observed between L-HFr and control or LDC rats for all spots. Four 
proteins significantly displayed more intense staining in the L-HFr-group (Figure 3.18). 
Intensity of one spot was significantly lower in the same group compared to the control 
or LDC group. 
 
 
Figure 3.18 Representative protein spots of phospho and silver stained 2-DE gels. Total protein 
hepatic lysate from Co, LDC or L-HFr fed rats was separated by 2-DE and then stained by phospho and 
siliver stain. Encircled differentially regulated proteins spots were identified using Delta 2D software. The 
figure shows exemplary protein spots from 2-DE gels of each experimental group. In addition, Delta 2D 
software was used for densitrometric analysis as illustrated in the bar chart as fold change (*P<0.05). Co: 
control, LDC: Lieber-DeCarli, L-HFr: LDC + 70% kcal fructose diet for 4 wks. 
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3.11. Expression of LCN2 in vitro 
3.12.1. Expression of LCN2 in isolated rat HCs was upregulated by fructose 
The rat primary HCs were isolated and cultured kinetically in M199 containing either 20 
mM glucose or fructose for 0, 3, 6, 12, and 24 h. After 6 h and 12 h, Lcn2 specific 
transcripts were more pronounced in fructose-incubated HCs than glucose-incubated 
HCs at the corresponding time points (Figure 3.19). 
 
 
Figure 3.19 Changes of Lcn2 expression in the isolated primary HCs. The rat cultured cells were 
kinetically incubated in either 20 mM glucose (Glu) or equimolar fructose (Fru) containing M199 medium 
for 0, 3, 6, 12 h. HCs: hepatocytes. 
 
The RT-PCR data were confirmed by Western blots (Figure 3.20). The time effect of 
the 20 mM dose of glucose on LCN2 expression in the HCs was minimal. Instead, in 
the first 3 h of fructose treatment the LCN2 expression evidently elevated upwards to 
12 h. All time points of fructose treatment showed a clear increase in expression of 
LCN2 compared to that found in equimolar glucose treatment. 
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Figure 3.20A Changes of LCN2 protein expression in cultured HCs. The rat cells were kinetically 




Figure 3.20B Densitometric analysis (I) and fold change (II) LCN2 expression. The HCs were 
kinetically treated with either 20 mM glucose or equimolar fructose containing M199 medium for 0, 3, 6, 
12 h. HCs: hepatocytes. 
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In the present study, the experimental animals were fed with a Co, LDC or L-HFr diet 
for 4 wks or 8 wks. The LDC and the L-HFr animal model developed fatty liver. The 
LDC diet induced simple steatosis, while L-HFr induced NASH and metabolic 
syndrome in the rats broadly as reflected in the pathophysiology of human NASH. A 
significant upregulation of LCN2 expression in the liver and serum was observed in 
the L-HFr induced NASH group. Indeed, LCN2 serves as a serological marker for 
diagnosis NASH in this animal model. Since LCN2 expression is influenced by 
inflammatory and other stressful conditions, its specificity is not yet well defined. The 
localization, the regulation and the role of LCN2 are still controversially discussed in 
the literature. However, in the present models the LCN2 positivity in the liver tissue 
was detected in PMN. 
4.1. Animal phenotypes and NAFLD 
Male Sprague-Dawley rats were used in this study due to their calmness and easy 
handling. In contrast to genetically identical inbred mice, the genetic polymorphism in 
these rats can be used to show the diversity of the responsiveness which appears in 
the population as a result of the genetic variety (Kacew and Festing 1996). Since sex 
hormones (e.g. estrogen) in the female animal increase fat deposition, LDL-C levels 
and obesity (Brown et al. 2010), and thus may interfere with the diet effects, male 
rats were preferred in this study. The other existing animal models were mostly 
genetically-modified ones, e.g. ob/ob, db/db, and ZF fa/fa, which do not mimic human 
conditions (Charlton et al. 2011). For instance, most features of steatohepatitis could 
be reproduced, but without features of the metabolic syndrome (ZF fa/fa) or vice 
versa (ob/ob and db/db) (Charlton et al. 2011; Takahashi et al. 2012). Another 
disadvantage of existing animal models is feeding the rats with a diet lacking choline 
and methionine, which creates a nutritional deficiency that is not common in patients 
with NASH but to which rodents are selectively sensitive (Lieber et al. 2004). 
Therefore, presence of a representative NAFLD animal models is of crucial impact, 
not only to elucidate the pathogenesis of simple steatosis to NASH, but also to 
investigate the therapeutic effects of various agents (Takahashi et al. 2012). 
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The LDC diet (36% kcal fat) is a nutritionally complete liquid diet widely used for 
modeling (in rodents) the pathological NAFLD changes manifested in humans 
(Bertola et al. 2013; Cohen et al. 2009). In these studies, the LDC diet resulted 
histologically in a simple hepatic steatosis (without inflammation), and no significant 
increases of serum TG concentration and activities of ALT and AST compared to 
chow diet (Lieber et al. 2004). Indeed, these features of the LDC animal model were 
exhibited in the current study. Hence, the LDC diet developed a typical simple 
steatosis in the rat liver. 
Fructose is included in commercial/fast food as well as juice beverages, and it is 
consumed frequently. It was shown in several animal experiments that a diet rich in 
fructose (e.g., up to 60% of the daily caloric intake) may lead to the development of 
NAFLD in rodents but may also result in the development of IR, dyslipidemia and 
oxidative stress (Spruss et al. 2012). Since the amount of uptake varies in human 
beings, several studies use different percentages of fructose (e.g. 30% kcal (Spruss 
et al. 2012) and 60% kcal (Haring and Harris 2011)) to investigate its effects on 
NAFLD and other metabolic disorders. Moreover, it has been reported that the onset 
of fructose-induced NAFLD is associated with intestinal bacterial overgrowth and/or 
increased intestinal permeability (Spruss et al. 2009). This facilitates the influx of LPS 
via portal blood and subsequent inflammation in the fatty liver (Spruss et al. 2012). 
Based on these studies, the L-HFr diet was selected to develop a NASH model and 
to investigate whether LCN2 could serve as a diagnostic biomarker. 
In the current study, there were no significant differences between the control and 
LDC groups regarding the total calorie consumption and initial as well as final BW. 
On the contrary, the highest food intake was observed in the L-HFr group. 
Unexpectedly, the BW of the L-HFr fed rats was reduced by 30% and 15% at wk 4 
and wk 8, respectively, compared to age-matched controls. However, the rats of this 
group possibly restore their BW if they are fed for longer. These findings were also 
described by Bruggeman et al. in their experiment where female rats were nourished 
with a high-fructose diet containing 10% kcal fat, 20% protein, 60% fructose, 10% 
corn (Bruggeman et al. 2011). The paradoxical correlation between food 
consumption and BW of the animals could be related to the hepatic inflammation 
seen in the L-HFr regimen especially at wk 4. In fact, the most pronounced elevation 
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of hepatic inflammatory mediators, such as Il-8, Mcp-1, α2-m and Tnf-α, was found at 
this time point. 
Up to 56% of NALFD patients present obesity and hepatomegaly at the time of 
physical examination (De Lusong et al. 2008; Paschos and Paletas 2009). Although 
the L-HFr fed rats showed a significant decrease in their BW compared to the Co 
group, visceral fat deposition and obvious hepatomegaly were observed in this 
group. Furthermore, the LW:BW ratio was significantly increased in the L-HFr fed rats 
similar to the findings of Bruggeman et al. (Bruggeman et al. 2011). Taken together, 
rats of the L-HFr group showed physical features comparable to human patients with 
NAFLD. 
4.2. The effect of the diets on the histopathological manifestations of NAFLD 
The LDC diet induced simple steatosis (NAFL type 1), while the L-HFr diet developed 
the typical criteria of hepatic lesions of NASH (NAFL type >2), namely extreme 
steatosis and moderate inflammation (grade 2) noticed mainly in zone I, whereas 
ongoing fibrosis was reproduced at both time points. Most importantly, NASH criteria 
(Angulo 2002; Tilg 2004) includes also a hepatocellular ballooning in the centrilobular 
areas. The presence of ballooned HCs is generally regarded to be a form of 
apoptosis (Tilg 2004; Yip and Burt 2006) and is associated with steatohepatitis, 
regardless whether its etiology was alcoholic or nonalcoholic (Lackner et al. 2008). 
According to the literature, these features are typical for human NASH (Charlton et al. 
2011). Indeed, under the L-HFr regimen, hepatocellular ballooning was often seen in 
the area surrounding the central vein. 
Although the pathogenesis of NASH has not yet been fully elucidated, a popular 
mechanism is the ”two-hit“ theory, in which the first hit is the accumulation of fatty 
acids in the liver (Lieber et al. 2004). One major promoting factor of this first hit is IR, 
which is present in most patients with NASH (Chitturi et al. 2002a). The second hit is 
the lipid peroxidation due to the oxidative stress produced by different factors, such 
as mitochondrial abnormalities, CYP2E1 induction, and endotoxins (Angulo and 
Lindor 2001). The 4-HNE adducts, by-products of lipid peroxidation, are also known 
to stimulate collagen (fibrosis) production (Houglum et al. 1990). In the present study, 
the fructose-supplemented diet induced more deleterious effects to the liver than the 
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LDC diet. Overall, the presence of ballooned HCs implies the development of NASH 
in the L-HFr group. Hence, the L-HFr regimen reproduces the key features of human 
NASH. 
4.3. Metabolic syndrome and serum transaminase 
Accompanied with NASH, the hallmarks of metabolic syndrome, e.g. an elevation of 
fasting plasma glucose, high TGs and low HDL-C levels, were found in humans 
(Adiels et al. 2006; Papakonstantinou et al. 2013). In contrast to the ZF fa/fa rat 
model (Charlton et al. 2011) and the LDC diet used in the current study, these 
features were indeed present in the L-HFr fed rats. Thus, this animal model is similar 
to the clinical pathophysiology of human NAFLD. 
After intestinal uptake, fructose is typically extracted from the blood stream by the 
HCs, independent of insulin exertion and the phosphofructokinase regulation step. 
Next, within the liver the acquired fructose is metabolized to glucose, fatty acids or 
lactate (Tappy and Le 2010). A significant upregulation of hepatic Glut5 (fructose 
transporter) gene expression was observed in the L-HFr nourished animals, which 
correlated with the accumulated fat in the liver. It has been stated that high fructose 
intake is associated with increased plasma TGs, most probably caused by an 
upregulation of hepatic de novo lipogenesis and TGs secretion, and a decreased 
clearance of VLDL-TG (Johnson et al. 2007). At this point, the L-HFr fed rats 
promoted the onset of massive hepatic steatosis mainly in zone I and II in this 
experiment. 
Circulating ALT and AST are known indicators of liver damage and present in very 
low concentrations in the circulation of healthy individuals (Yuzer et al. 2009). On 
contrast, most of the patients with simple steatosis are usually clinically 
asymptomatic, whereas their serum transaminase levels may be elevated, most 
frequently serum ALT (Ekstedt et al. 2006; Yu and Keeffe 2003). It was also reported 
that a low normal ALT value does not guarantee freedom from underlying 
steatohepatitis, especially when there is advanced fibrosis (Mofrad et al. 2003). In 
fact, the activities of serum ALT and AST in the LDC regimen were mildly higher than 
the control but not significantly so. This finding is also not uncommon in the human 
disease, for which a significant increase in ALT activity has been reported in less 
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than one-third of the patients (Diehl et al. 1988; Lieber et al. 2004). In fact, the L-HFr 
group showed a significant increase in the serum transaminase activities as found in 
most human cases with NASH (Francque et al. 2012). Thus, a reliable predictor to 
differentiate between the simple steatosis and NASH is still required. 
The L-HFr diet induced a substantial elevation of fasting leptin levels. It has been 
stated that fructose promotes leptin resistance in rodents and humans (Gray et al. 
2013; Shapiro et al. 2008), whereby the leptin action was suppressed and did not 
induce satiation (fullness). In this context, there are two popular mouse models of a 
spontaneous mutation in the leptin ob/ob or its receptor db/db gene. The ob/ob mice 
are hyperphagic (eat extensively), inactive and extremely obese. The db/db mice 
show normal or elevated levels of leptin but are resistant to the effects of leptin 
(Takahashi et al. 2012). This possibly explains the increased food consumption noted 
in the L-HFr group compared to the Co or the LDC groups. 
The advantage of ob/ob and db/db mice is that the phenotype of these mice 
simulates the human condition of the metabolic syndrome in many aspects except 
physiological leptin levels and/or action (Nagarajan et al. 2012; Takahashi et al. 
2012). While both models develop spontaneous hepatic steatosis, it does not 
progress spontaneously to steatohepatitis or fibrosis (Takahashi et al. 2012). Leptin 
is not only a critical regulator of BW and appetite, but its role as a proinflammatory 
mediator has also gained attention in NASH (Chatterjee et al. 2013). In NASH 
patients serum leptin levels are increased compared with gender and BMI matched 
controls (Chitturi et al. 2002b). Furthermore, serum leptin levels were independently 
associated with the amount of steatosis and inflammation but not with fibrosis 
(Chitturi et al. 2002b). Together, key features of the metabolic syndrome and 
elevated serum transaminase activities under the L-HFr regimen are similar to 
pathological conditions seen in humans. 
4.4. LCN2 expression in the liver and serum of L-HFr fed rats 
It has been reported that the expression of LCN2 is influenced by pro-inflammatory 
factors (Fujino et al. 2006). In addition, the studies showed that LCN2 has emerged 
as a potential link between obesity, inflammation, and obesity-associated metabolic 
dysfunction such as IR (Wang et al. 2007). 
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The expression of hepatic LCN2 was significantly increased at gene as well as 
protein levels accompanied by elevated serum level in the L-HFr regimen compared 
to the Co or the LDC group at wk 4 and wk 8, respectively. As the LDC group showed 
primarily simple steatosis, it can be considered as a control for the L-HFr induced 
NASH group. While the LDC as well as the L-HFr models showed fatty liver, the 
significant expression of LCN2 in the liver and serum was seen in the L-HFr model. 
Thus, LCN2 is a biomarker for NASH in the present study. 
Studies of NAFLD in humans have limitations. This is due to the fact that progression 
of simple steatosis to NASH takes years, and the ethical limitations in administering 
drugs to or collecting liver tissues from patients (Takahashi et al. 2012). The tools 
widely used for assessment of NAFLD cannot classify the stage of the disease 
(Tarasow et al. 2002). Biopsy studies show that progression of NASH to fibrosis 
occurs in approximately 40% of patients, but most of these patients do not show 
clinical or biochemical deterioration (Lall et al. 2008). Also, routine liver function tests, 
such as serum ALT activity, cannot guarantee absence of underlying steatohepatitis 
(Mofrad et al. 2003). Thus, there is a need for a reliable noninvasive biomarker to 
monitor the shift from simple steatosis (benign and readily reversible form (Hubscher 
2004)) to NASH (a progressing form). In this study, the increased systemic LCN2 
level in the L-HFr group could be shown. However, specificity of the LCN2 as a 
diagnostic indicator is low unless other causes of liver inflammation can be excluded. 
The following factors that induce liver inflammation should be considered: γ-
irradiation, turpentine oil toxins, medical drugs (Patel and Sanyal 2013) and 
autoimmune cholangiopathies. The general goal in the treatment of NASH is to 
correct risk factors with exercise and appropriate diet and to avoid drugs such as 
tamoxifen and steroids which exacerbate liver disease (Lall et al. 2008). 
4.5. Localization and possible role of LCN2 in the liver 
As most experimental models that studied LCN2 were with Lcn2KO mice, no focus 
was placed on the localization of this protein in the liver. Hence, the pathological 
significance of the localization of LCN2 in the liver needs clarification. In the present 
study, a double-immunofluorescence staining was performed to detect LCN2 co-
localization with MPO+ and/or ED1+ cells in the liver tissues. This immunostaining 
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demonstrated hepatic LCN2 positivity in MPO+ neutrophil granulocytes and confirms 
previous findings in  the literature (Sultan et al. 2013).  
One study that defines the localization of LCN2 in mice fatty liver found LCN2-
expressing HCs were localized around the inflammatory cell clusters (Semba et al. 
2013). However, immunoperoxidase staining with a single antibody was used to 
detect hepatic LCN2 positivity in this study (Semba et al. 2013). Thus, exact 
localization of LCN2 in the liver will be rather difficult. Similarly, another study 
detected LCN2 positivity in HCs of liver sections using the same method (Borkham-
Kamphorst et al. 2011) (Appendix Table 1).  
The studies (Borkham-Kamphorst et al. 2011; Sultan et al. 2013; Sultan et al. 2012) 
that found increased Lcn2 expression by various stimuli in primary rat HCs used the 
cell isolation method according to Seglen (Seglen 1973). It has been reported that 
unlike LCN2 expression in cultured HSC, freshly isolated HCs do not express LCN2. 
Upon culturing, however, the respective mRNA and protein levels increased 
dramatically in time-dependent fashion (Borkham-Kamphorst et al. 2011) probably 
owing to the fact that conventional monolayers of cultured HCs develop autocrine 
TGF-β-mediated apoptosis (Gressner et al. 1997). However, Seglen’s method was 
discussed as a method of HCs enrichment, as the purity of the HCs is 90%, thus it is 
not an absolutely pure method (Ates M et al. 2012; Wojcik et al., 2012). Primary rat 
HCs were isolated and treated with 20 mM glucose or fructose in the current study. 
Fructose-treated HCs significantly expressed LCN2. In comparison to in vivo studies, 
where Lcn2 mRNA expression in liver showed a 90-fold and 507-fold increase at wk 
4 and wk 8, respectively, the Lcn2 gene expression was maximally 2.5-fold higher 
than in controls of the cultured HCs. 
Although it was able to detect the expression of the hepatic LCN2 in the L-HFr-fed 
rats by WB in this study, the immunofluorescence staining did not show LCN2+ HCs 
in rat’s liver. In addition, there were no significant changes in the proteins in the range 
of 20-37 kDa by using 2-DE analysis. These findings indicate that LCN2 (25 kDa) is 
most probably expressed by a minority of liver cells than in HCs. Indeed, it was 
previously shown that a macrophage-specific protein was not detectable in liver total 
homogenates by using 2-DE. In contrast, this protein was clearly detectable in protein 
extracts from a macrophage cell line using the same method (Wojcik et al. 2012). 
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The sensitivity of WB is higher than normal 2-DE (Kumar et al. 2013; Wise and Lin 
1991). Since most proteins of total liver homogenates are from HCs, the percentage 
of proteins from PMN may beyond the sensitivity of 2-DE detection. This implies that 
other cell type (most probably PMN) rather than HCs could be the responsible cells 
for Lcn2 expression in vivo as confirmed by the results of the immunofluorescence 
staining presented in this study. 
The likelihood that changes in the concentration of hepatic fructose and its 
metabolites after intake could potentiate lipid peroxidation, alterations of endoplasmic 
reticulum and mitochondrial functions was assessed by 4-HNE adducts, GRP78, 
casp 9, Cyt c and PGC-1α. The expression of 4-HNE adducts was markedly higher in 
L-HFr fed rats than in controls. This result is similar to findings of other studies in 
rodent models of diet induced NAFLD (Armutcu et al. 2005), suggesting that the 
formation of ROS in the L-HFr group was markedly enhanced or ROS were less 
efficiently quenched. The hepatic oxidative stress in fructose-induced fatty liver is not 
caused by sulfur amino acid insufficiency (Kunde et al. 2011). Augmentations of 
GRP78, casp 9 and Cyt c expression were also noticed in L-HFr fed rats, suggesting 
that these rats, compared with the LDC or chow-fed rats, were facing elevated 
oxidative stress conditions. Additionally, 4-HNE chemotactically recruits PMN into the 
stressed liver (Figure 4.1). 
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Figure 4.1 Hypothetical model of the mechanism of hepatic LCN2 production in L-HFr. Ingested 
fructose is delivered into the liver via portal vein. Once inside the liver, hepatocytes transformed 
fructose into FFAs and TGs. As a result of fat accumulation in hepatocytes, lipid peroxidation end 
products (e.g. 4-HNE), iNOS and other cytokines/chemokines will be produced, which could recruit 
PMN to the liver. In addition, chronic fructose consumption facilitates the influx of endotoxins (LPS) 
into the liver. Endotoxins stimulate KCs which, in turn, release ROS and cytokines. This results in 
recruitment of more PMN and monocytes to the liver. Further studies are needed to investigate 
whether LCN2 could act as hepatoprotective protein. KCs: Kupffer cells, PMN: polymorphonuclear 
neutrophils, PV: portal vein. 
 
Although the cleaved casp 9 and the release of Cyto c were not measured in the 
current study, an important mitochondrial-biogenic protein (PGC-1α) was explored. It 
was regarded that PGC-1α expression in the liver is normally increased during 
fasting in response to glucagon (Herzig et al. 2001), and it also plays a central role in 
the regulation of cellular energy metabolism (Liang and Ward 2006) and 
mitochondrial function (Holmstrom et al. 2012). Interestingly, the protein expression 
of PGC-1α was predominantly at wk 8 in livers from the L-HFr group. This was 
consistent with hepatocellular ballooning, providing further evidence for a decreased 
mitochondrial function. Taken together, these results indicated that chronic fructose-
enriched diet altered, at least partially, mitochondrial and endoplasmic reticulum 
functions and induced cellular apoptosis and stress conditions. These conditions 
were associated with the significant increase in LCN2 expression. 
It has been emphasized that fructose consumption is also correlated with elevated 
LPS levels in the liver, which can trigger the release of proinflammatory cytokines 
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when bound to CD14/TLR4 which are present in immune cells (Baker et al. 2011). 
Recognition of LPS by the CD14/TLR4/MD-2 complex activates intracellular signaling 
pathways involving MAPK, resulting in the production of proinflammatory cytokines 
and chemokines (Lin et al. 2004). It is known that chronic endotoxin that induces 
TLR4 activation can also induce liver fibrosis (Paik et al. 2003). Indeed, upregulated 
levels of hepatic TLR4, CD14 and p/ERK1/2 in L-HFr regimen were found at wk 4. In 
addition, the L-HFr diet potentiated stronger fibrosis - as observed by Masson’s 
Trichrome staining - than the LDC and the Co diet. The multifunctional CD14, 
however, was also elevated in livers of the L-HFr group at wk 8. CD14, in addition to 
its important role in inflammation and innate immunity, promotes cell survival and 
antagonizes programmed cell death ‘‘apoptosis’’ (Heidenreich 1999). Overall, these 
findings, indirectly, suggest that the influx of endotoxins from the bowel into the liver 
via the portal vein could also be involved in the modulation of liver inflammation in L-
HFr-treated rats by TLR4-dependent manner (Anurag and Anuradha 2002) (Figure 
4.1). 
Actually, several Lcn2 knockout mouse models have been used to study the role of 
LCN2 in the liver. However, the data are controversial regarding whether LCN2 plays 
a role in recruiting the inflammatory cells to the site of injury and exacerbating the 
local inflammation (Pedersen et al. 2001), and regarding its role as an anti-
inflammatory and protective protein (Zhang et al. 2008). In addition, the role of LCN2 
in glucose metabolism and IR also remains contradictory (Guo et al. 2010; Jun et al. 
2011). However, in the current study LCN2 is elevated in fructose-induced 
steatohepatitis, and thus it is a marker for hepatic inflammation. Functional studies 
are needed to evaluate, whether LCN2 upregulation might have a hepato-protective 
function. 
4.6. Conclusion 
Both of the applied diets induced NAFLD. While the LDC diet led to a simple 
steatosis, the L-HFr diet resulted in NASH. Fructose supplementation appears to 
worsen liver pathology. The key features of the metabolic syndrome and NASH with 
progressive fibrosis represent an animal model broadly similar to the typical 
conditions in human NASH. These findings highlight the impact of dietary 
composition in the development of NAFLD. The fructose diet upregulates hepatic 
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LCN2 gene expression in fructose-induced NASH. This correlates with increased 
indicators of inflammation, oxidative stress, and mitochondrial dysfunction. As the 
hallmarks of human pathophysiology were reproduced in this novel study, serum 
LCN2 could be emerging as a useful new biomarker to discriminate between simple 
steatosis and NASH. Evidently, an interaction exists between the metabolic impetus 
and inflammatory processes in the animals. The diet described in this study provides 
a useful model for further LCN2 studies in depth and the development of new insights 
for preventing NASH. 
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The high-fructose induced NASH model may be used in further studies on the role of 
LCN2 in apoptosis. In addition, this model could be extended to study whether LCN2 
are involved in liver protection, e.g. as a LPS-neutralizing factor. With this fructose rat 
model, additional biomarkers with higher specificity should be investigated. Since the 
present study highlights the controversial role of LCN2 in inflammation and insulin 
resistance, further studies should investigate this issue. Similarly, as the LCN2 
localization remains controversial its significance deserves to be investigated. 
Translating the findings of the present model into human samples will reveal valuable 
insights into the pathogenesis of NASH in humans. 
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Appendix Figure 1 Kinetic HE staining for rat liver sections on 1, 2, 4, 8 wks. The whole experiment 
was designed as 1, 2, 4, and 8 wks. In this dissertation, I focused of 4 and 8 wks to simplify the study. 
Co: chow diet, LDC: Lieber-DeCarli, and L-HFr: LDC+ 70% kcal fructose. 
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Appendix Table 1 Summary of LCN2 studies in recent literature 
 Author Model/design Tissue Treatment Title/Conclusion 
1 Semba 
2013 
Fatty liver Shionogi 




Chow pellets The FLS mouse reveals 
local expressions of LCN2 
and CXCL9 in the liver with 
NASH, suggesting significant 
roles of these proteins in the 
















Protective effects of LCN2 in 
acute liver injury suggest a 
novel function in liver 
homeostasis. 
3 Jun 2011 Lcn2¯
/









A minor role for LCN2 in 
HFD induced glucose 
intolerance. 
4 Liu 2011 18-yr-old men Serum cross-section 
study 
LCN2 is not an independent 













Induction of LCN2 
expression in acute and 
chronic exp. liver injury 
moderated by pro-
infammatory IL-1β through 
NF-kB activation. 








LCN2 deficiency prevents 
endothelial dysfunction 
associated with obesity. 
7 Guo 2010 Lcn2¯
/









LCN2 deficiency impairs 
thermogenesis and 
potentiates diet-induced IR 
in mice. 














LCN2 deficiency protects 
mice from developing aging- 















LCN2 Is an Inflammatory 
marker closely associated 
with obesity, IR, and 
hyperglycemia in Humans. 
HFD: high fat diet. 
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